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ABSTRACT
The immunodynamics of HIV infection have been studied for over three decades 
in the hopes of determining underlying mechanisms that contribute to the sustained 
immune dysfunction observed even in individuals on therapy. Conventional and 
adaptive T cells are both the target of the virus and considered the main  players in 
controlling viral burden. However, there are unconventional T cells with innate-
like, rapid effector functions that are also altered in HIV infection. Among these 
are iNKT cells and MAIT cells, which both decline in frequency, are dysfunctional, 
and have an altered phenotype in the blood in chronic HIV infection. The dynamics 
of their loss, phenotype, and dysfunction are a major focus of this thesis. In order 
to study MAIT and iNKT cell dynamics in acute HIV-1 infection, the unique acute 
HIV infection cohort, RV217, was used with donor matched pre- and post- HIV 
infection blood samples in the acute infection stage. An additional study where 
ART is initiated in the acute infection stage, RV254, which collected both blood 
and rectosigmoid biopsy samples, was also used. This cohort allowed for both the 
study colonic MAIT and iNKT cell dynamics in acute HIV infection, as well as 
the impact of early ART initiation on blood and colonic iNKT cells. In Paper I, 
an optimized multiparameter immunofluorescence panel (OMIP) was generated 
to measure the frequency and phenotype of iNKT and MAIT cells in  individuals 
from RV217. In Paper II, detailed studies of the RV217 cohort revealed that 
MAIT cells express markers of activation and exhaustion, and briefly expand 
alongside an elevated functional capacity in the acute infection stage. However, 
by 3 months post-infection the MAIT cell response to E. coli stimulation in vitro 
declined. Total transcriptome analysis showed that MAIT cells upregulate an 
innate-like transcriptional signature. This finding, coupled with the expansion of 
a subset of MAIT cells that express the NK-cell receptor CD56 and produce more 
RIWKHDQWLYLUDOF\WRNLQH,)1ȖLQUHVSRQVHWRLQQDWHF\WRNLQHVWLPXODWLRQ,/
and IL-18 in vitro, suggests that MAIT cells become progressively more innate-
like during the course of acute HIV infection. The OMIP was also used to study 
iNKT cells in acute HIV-1 infection in Paper III. The RV217 cohort showed that 
iNKT cells are preferentially depleted in the blood in acute HIV infection, par-
ticularly CD4+ iNKT cells. Remaining iNKT cells express markers of activation 
and become dysfunctional during acute infection. Colonic samples revealed that 
CD4+ iNKT cells are depleted more substantially than in the blood in the acute 
infection stage. The early ART treatment cohort, RV254, demonstrated that early 
ART initiation is able to prevent iNKT cell activation and depletion in the blood, 
but unable to stop their depletion in the colon during acute HIV infection. The 
work in Paper IV, shows that conventional adaptive CD8 T cells can develop an 
LQQDWHOLNHIXQFWLRQDOLW\PHGLDWHGE\WKH)FȖ5,,,$&'GXULQJFKURQLFVWDJHV
of HIV infection. Expression of CD16 occurs in late-stage differentiated CD8 
T cells, is associated with expression of the IKZF2 transcription factor (Helios) 
DQGDQ1.S,/5ĮVXUIDFHSKHQRW\SH,QWHUHVWLQJO\WKLV&'7FHOOVXEVHW
mediates antibody-dependent cellular cytotoxicity (ADCC) against HIV protein 
coated target cells at a level on par with NK cells on a per cell basis. In summary, 
the work in this thesis sheds new light on the behavior and responses of unconven-
tional T cell subsets during acute HIV infection. Furthermore, the work defines 
a novel function of conventional adaptive CD8 T cells in chronic HIV infection. 
Altogether, this thesis provides new insights on the role of innate-like functions 
in the human T cell compartment in the immunopathogenesis of HIV-1 infection.
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11 INTRODUCTION
1.1 The innate and adaptive immune system
The human immune system works as an elegant, evolutionarily selected system to 
protect the body against the assault humans undergo daily from pathogens. This 
collection of cells, molecules, and protective physical barriers that contribute to the 
immune system are often categorized into two subsystems; adaptive/acquired and 
innate immunity. Innate immunity is the first to respond to pathogens and respond 
within hours of infiltration. Days to weeks later, a highly antigen specific adaptive 
immune response emerges. Several hundred million years older than the adap-
tive immune system, innate immunity is highly evolutionarily conserved across 
vertebrates (1, 2). The human innate immune system consists of physical barriers 
like skin, cellular components such as phagocytic and granular cells including 
macrophages, dendritic cells, and neutrophils, and humoral components like com-
plement. Innate immune cells may recognize non-self molecules through pattern 
recognition receptors (PRRs) that bind to conserved pathogen-associated molecular 
patterns (PAMPs), such as viral RNA or bacterially-derived lipopolysaccharide 
(LPS) (3). Toll-like receptors (TLRs) are PRRs expressed in a variety of myeloid 
cell types such as monocytes. Cell surface expression of TLR4 on monocytes, for 
instance, can recognize bacterially-derived LPS and elicit the transcription and 
production of pro-inflammatory cytokines and type-1 interferon from monocytes, 
thus engaging the recruitment of other immune cells to combat the pathogen (4). 
Similar to innate immunity, the adaptive response is composed of humoral and 
cellular components. The main cellular components in adaptive immunity are B 
and T lymphocytes. B cells will generate humoral immunity through their  ability 
to produce circulating antibodies. T cells provide cellular immunity and elicit cell 
based effector functions. B cells and T cells are able to recognize foreign anti-
gen with exquisite specificity based on the somatic recombination of their B cell 
receptor (BCR) or T cell receptor (TCR), respectively. The genes that encode 
these receptors undergo somatic recombination of the variable (V), diversity (D) 
and joining (J) segments, allowing for the formation of a unique gene within each 
lymphocyte encoding their respective BCR or TCR. Consequently, these uniquely 
encoded BCRs and TCRs can recognize distinctive antigens. This allows for a 
diverse collection of BCRs and TCRs in the body, each expressed by their own 
B or T cell, respectively, that facilitate the recognition of a multitude of antigens 
(5). The B cell BCR can exist as a membrane-bound cell signaling antibody (Ab) 
or can be secreted in the form of an effector antibody. Antibodies have two major 
components. The antigen-binding region of the antibody is known as the F’ab 
region, and the Fc region is the effector portion that binds to cellular Fc-receptors.
21.2 Conventional and unconventional T cell subsets 
and recognition of their cognate antigens
1.2.1 Conventional, adaptive CD8 T cells
The TCR of a T cell is only found in its membrane-bound form and is used for 
antigen recognition and signal transduction (1). The TCR occurs as the more 
DEXQGDQWĮȕKHWHURGLPHUUHSUHVHQWLQJXSZDUGVRIRIWRWDO7FHOOVRUWKH
UDUHUȖįKHWHURGLPHU&RQYHQWLRQDOSRO\PRUSKLF7FHOOVFDQEHGLYLGHGLQWR&'
expressing helper T cells, or CD8 expressing cytotoxic T cells. CD8 and CD4 T 
cells recognize peptide antigens presented in the context of MHC-I or MHC-II, 
respectively (Figure 1). One of the aims of this thesis focuses on an innate-like 
adaptive CD8 T cell subset. Therefore, for now I will only focus on the biology 
of conventional, adaptive CD8 T cells.
The fundamental paradigm that cytotoxic T cells recognize foreign antigen in the 
context of a self-antigen presenting molecule was first discovered in 1974 using a 
mouse model of LCMV infection (6). Since then it has been appreciated that CD8 
T cells (CD3+) have high antigenic specificity towards peptide antigen presented in 
the context of MHC-I (Figure 1) (7). The CD8 TCR recognizes antigenic peptides 
that are 8-10 amino acids in length. Antigenic stimulation of a naïve, or antigen-
inexperienced, CD8 T cell also requires costimulation of the activating receptor 
CD28, which binds with CD80 or CD86 expressed by an antigen presenting cell 
(APC), and a pro-inflammatory signal such as IL-12 or type-1 interferon (8). An 
effector CD8 T cell response against the presented antigen is mounted over the 
course of 1-2 weeks after initial TCR engagement. These antigen-specific effector 
CD8 T cells elicit cytotoxic effector functions on target cells expressing its cognate 
antigen. This is done through the delivery of cytoplasmic granular molecules into 
the target cell, a process known as degranulation. Within the granular molecules 
are perforin, a pore-forming molecule that makes pores in the plasma membrane 
of the target cell (9). Serine proteases, known as granzymes, are also included in 
these granular molecules, and facilitate cleavage of caspases and the initiation of 
apoptosis within the target cell (10).
T cells that share the same TCR are known as clonotypes, and it is estimated 
that there are approximately 1010 unique clonotypes within the human body (11, 
12). Antigen recognition by the TCR causes the antigenic-specific clonotypes to 
undergo massive proliferation, transcriptional alteration, and gain tissue homing 
capability. This event is known as clonal expansion, where an antigen-specific 
CD8 T cell expands from a low frequency of naïve cells to millions of effector 
cells (13-15). After antigenic clearance, presumably due to pathogen clearance, 
the specific CD8 T cell population undergoes a contraction phase wherein the 
 majority of the clonally expanded cells die via apoptosis. There are, however, 
a subset of antigen-specific cells that enter long-term quiescence and become 
3memory CD8 T cells. Memory CD8 T cells can respond with rapid effector func-
tion upon restimulation with antigen, and that immunological memory may last 
the lifetime of the host (Figure 3) (16). These long-term memory effector cells 
are a mechanism to clear previously-eliminated pathogens upon re-exposure. The 
transition of a CD8 T cell from antigen-naïve to a memory T cell comes with it a 
changing phenotype, function and location in the body, with varying expression 
RIVXUIDFHPDUNHUVVXFKDV&'&'52&'5$&'/&',/5Į
CD27, and CCR7, summarized in Table 1 (17-23). 
Table 1. Descriptive characteristics of the maturation of adaptive CD8 T cells.
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Information gathered from (23, 24).
There are instances where antigens can persist, such as in chronic inflammation 
and chronic viral infections, such as HIV-1 (HIV for the remainder of this thesis) 
infection (25). It is in these instances where CD8 T cells can become “exhausted,” 
with altered phenotypic profiles, effector responses, and transcriptional regulation. 
An exhausted CD8 T cell population can lead to incomplete pathogenic clearance 
and dysfunctional immune response (25, 26). In particular, persistent TCR cell 
stimulation leads to exhausted antigen-specific T cells, and this impaired function-
ality of CD8 T cells is often described in HIV, hepatitis B virus (HBV), hepatitis 
C virus (HCV) infection, as well as cancer in humans (27). 
In instances of chronic TCR stimulation, such as a persistent viral infection, the 
ability of CD8 T cells to produce cytokines is lost in a step-wise manner, with IL-2 
and TNF production lost first. This can be followed by a decreased ability to pro-
GXFH,)1ȖDQGF\WRWR[LFPROHFXOHV28-30). TCR-mediated exhaustion of a CD8 
T cell can induce altered transcriptional expression of nuclear factor of activated 
T cells (NFAT) and sprouty homologue 2 (SPRY2), which is consistent with a role 
4for ongoing TCR stimulation (31, 32). Along with this, an exhausted CD8 T cell 
upregulates surface expression of a number of inhibitory molecules, a phenotype 
also observed in antigen-specific T cell populations in chronic viral infections. 
Examples of such molecules are the checkpoint inhibitor programmed cell death 
protein 1 (PD1), lymphocyte activation gene 3 protein (LAG3), 2B4, CD160, 
cytotoxic T-lymphocyte-associated protein 4 (CTLA4), and T cell immunoreceptor 
with immunoglobulin and ITIM domains (TIGIT) (33-35). This exhausted pheno-
type is accompanied by decreased proliferative capacity, and loss of the ability to 
self-renew in an IL-7 and IL-15 dependent fashion (34). Expression of Eomes and 
T-bet, transcription factors responsible for maintaining the homeostasis of memory 
T cell function through the modulation of checkpoint inhibitor expression, can 
further delineate exhausted CD8 T cells (36, 37). The coexpression of inhibitory 
molecules PD-1, CD160, and 2B4, the expression of which are elevated in chronic 
HIV infection (CHI), correlates with a T-betdim Eomeshi transcription factor profile 
amongst HIV-specific CD8 T cells (38). Virus-specific EomeshiPD1hi exhausted 
CD8 T cells have been identified in chronic HCV and HIV infection and are likely 
driven by chronic antigen exposure (38, 39). Despite the potential for exhaustion 
in these states, the response of adaptive, conventional CD8 T cell is critical for 
controlling pathogens in the host.
Figure 1. Conventional and unconventional T cells and recognition of their cognate 
antigens. Unlike conventional CD4 and CD8 T cells that have variable TCR chains that 
recognize peptide antigen, MAIT cells and iNKT cells have invariant TCR chains that 
recognize antigen presented in conserved MHC-I-like molecules that present riboflavin 
metabolites or glycolipids, respectively. Reprinted with permission from (40). 
1.2.2 Mucosal associated invariant T (MAIT) cells
In between the conventional, adaptive T cells and innate effector cells such as 
natural killer (NK) cells, there is a family of unconventional T cells that recog-
nize non-polymorphic MHC-I-like molecules that present nonpeptide antigens 
(Figure 1). Mucosal associated invariant T (MAIT) and invariant natural killer T 
5(iNKT) cells are amongst these unconventional T cells and respond to their cognate 
antigen in a rapid innate-like fashion. Unlike conventional T cells that need many 
days to weeks to mount an antigen-specific response and gain memory after anti-
genic exposure, the unconventional T cells MAIT and iNKT cells can be activated 
and respond within hours of exposure to foreign pathogens, and exhibit an effec-
tor memory phenotype prior to antigen exposure in the periphery (Table 1) (41). 
This allows for a buffer of time for conventional T cells to mount their adaptive, 
antigen-specific response (Figure 2). Upon reactivation with their cognate antigen, 
conventional adaptive T cells that have attained memory can respond more rapidly 
than their naïve counter parts, in a manner almost in tune with unconventional T 
cells (Figure 2). While most T cells have highly variable TCRs the MAIT and iNKT 
cells express semi-invariant or invariant TCRs, respectively, that have undergone 
somatic rearrangement (42). This thesis aims to further elucidate the role of iNKT 
and MAIT cells in HIV infection.
Figure 2. The temporal dynamics of unconventional and conventional T cell responses to 
their cognate antigen. Unconventional T cells, including iNKT and MAIT cells, respond to 
stimulation within hours of their activation. Conventional T cells will take days to weeks to 
mount their response and at a weaker functional magnitude compared to conventional T cells. 
However, upon generation of immunological memory, conventional T cells can respond to 
stimulation at a faster pace and stronger magnitude, akin to unconventional T cells, which 
already poses an effector memory phenotype prior to antigen recognition in the periphery. 
Material from: Godfrey et al., Nature Immunology, 2015, Nature Publishing (43)
0$,7FHOOVLQSDUWLFXODUH[LVWLQODUJHQXPEHUVLQKHDOWK\KXPDQVXSWRRI
the circulating T cell pool, and thus form a formidable part of the immune defense 
(44-47). MAIT cells can be found throughout the body, including tissues such as 
WKHJDVWURLQWHVWLQDORU³JXW´PXFRVDRIWRWDOJXWDVVRFLDWHG7FHOOVDQGWKH
OLYHUZKHUHWKH\DUHPRVWDEXQGDQWO\REVHUYHGRIWRWDO7FHOOV44, 48-51). 
There are relatively few MAIT cells in the thymus, but their numbers expand in 
the periphery (52). Functionally competent MAIT cells have been identified in the 
cord blood and human fetal tissue, albeit with a naïve phenotype including surface 
6expression of CD45RA (Table 1). The development of a central memory pheno-
type as is found in adults is thought to occur within the first year of life, possibly 
stimulated by the establishment of the commensal flora (51, 53, 54). The frequency 
of MAIT cells in the blood is lower in children, peaks in young adulthood, and 
declines in the elderly (55).
,QKXPDQV0$,7FHOOVH[SUHVVWKHLQYDULDQW9Į7&5FKDLQOLPLWHG-ĮVHJPHQWV
-Į-ĮDQG-ĮDQGKDYHDOLPLWHGȕFKDLQUHSHUWRLUH43, 56-60). Their 
TCR recognizes microbially derived pyrimidine intermediates from the riboflavin 
biosynthesis pathway that are presented in the context of major histocompability 
complex class Ib-like molecule 1 (MR1) (45, 47, 61-63). MR1 is ubiquitously 
expressed at the gene level in the majority of human lymphocytes and APCs in 
the blood, and is highly evolutionarily conserved (45, 47, 61-63). Thymic MAIT 
cells require engagement with MR1 and an unknown antigen in order to develop 
and egress into the periphery (52). The ability to metabolize riboflavin is found 
in many bacteria and fungi, implicating MAIT cells in immunity against a vast 
range of microbial infections (62). 
Great advances have been made to identify MAIT cells, which express high levels 
of the C-type lectin CD161 (KLRB1), a marker commonly associated with NK 
cells and innate-like functionality. CD161 can be found on CD8 T cells as either 
CD161dim or CD161bright, with the majority of the latter being MAIT cells (64). The 
role of CD161 on MAIT cells has yet to be determined, but MAIT cells have clas-
sically been identified in flow cytometry through the coexpression of CD161bright 
DQGWKH7&59ĮDPRQJVW&'7FHOOV65, 66). With the identification of a 
main MAIT activating antigen, 5-(2-oxopropylideneamino)-6-D-ribitylaminou-
racil (5-OP-RU), MR1 tetramer can also be used to identify MAIT cells by flow 
cytometry, and encompass the vast majority of CD161bright9Į7FHOOV67). In 
DGGLWLRQ0$,7FHOOVH[SUHVVKLJKOHYHOVRI,/5ĮDQG,/5DOORZLQJWKHP
to be activated in a TCR-independent manner through innate cytokine stimula-
tion (Figure 3). They acquire expression of the transcription factor promyelocytic 
leukemia zinc finger (PLZF) (ZBTB16) in the thymus. This transcription factor 
is also expressed in iNKT cells and is believed to play a role in innateness and 
the pro-apoptotic nature of these cells (49, 68, 69). MAIT cells can express CD8 
DQGDUHSULPDULO\&'ĮĮ!EXWFDQEHH[SUHVVWKH&'ĮȕKHWHURGLPHU
(70:KLOHJUHDWHUWKDQRI0$,7FHOOVH[SUHVV&'LQKXPDQVDVPDOOHU
proportion of MAIT cells lack expression of both CD4 and CD8 and are deemed 
GRXEOHQHJDWLYH'1$QHYHQVPDOOHUVXEVHWH[SUHVVHV&'49, 
58, 68, 70). Their CD8 expression reflects their cytotoxic potential, and ligation of 
their TCR with antigen-loaded MR1 elicits rapid and broad cytokine production 
in both the blood and mucosal sites. MAIT cells can production of TH1 cytokines 
VXFKDVLQWHUIHURQ,)1ȖWXPRUQHFURVLVIDFWRU71)DQGF\WRWR[LFPROHFXOHV
such as granzyme (Grz) to deliver to target cells and induce cell death (Figure 3) 
7(62, 70, 71). Ex vivo studies demonstrate that mucosal MAIT cells can produce 
IL-17 and IL-22 and may contribute to mucosal immunity (42, 46-48). Peripheral 
blood MAIT cells can express these cytokines at lower levels, but predominantly 
produce granzymes and TH1 cytokines but not TH2 cytokines in vitro (58, 70, 72, 
73). Recently, it was determined that the education of the TH17 MAIT cell subset 
occurs in the thymus upon establishment of commensal microbiome (44, 48-50, 74). 
Their ability to produce a wide range of cytokines in response to microbially-
derived antigen in both the peripheral blood and mucosal sites implicates MAIT 
cells in combating bacterial and fungal pathogens. MR1 knockout mice lacking 
MAIT cells due to the lack of MR1 education in the thymus, have higher bacterial 
loads upon challenge with of Francisella tularensis, Klebsiella pneumoniae, and 
Mycobacterium bovis (75-77). Humans with cystitis have MAIT cells present in 
their urine, and patients with active tuberculosis (TB) have an increase in MAIT 
cells in the lung. These findings support a notion that MAIT cells assist with bac-
terial control at the site of infection and are recruited to places of bacterial infec-
tion (78, 79). Furthermore, MR1 knockout mice have lowered gut integrity and an 
infiltration of bacterial DNA in the peripheral blood compared to mice that have 
MAIT cells, suggesting a role for MAIT cells in protecting gut homeostasis (80). 
Studies in mice also demonstrate MAIT cells acquire a tissue-repair gene signa-
ture after the resolution of a bacterial infection. This finding points towards a role 
for MAIT cells in wound repair. It may be that damage to the mucosa results in 
engagement of the MAIT cell TCR with either commensal or pathogenic bacteria 
to not only induce a proinflammatory response to clear the bacterial invasion, but 
also begin assisting in the healing process of the damaged tissue (81).
Peripheral blood MAIT cells in adults display an effector memory (CD45RO+ 
CD28+CD62L-CCR7-) phenotype and express an array of surface receptors 
DVVRFLDWHGZLWKWLVVXHKRPLQJVXFKDVĮȕ&&5&&5&&5&;&5DQG
CCR9 (44, 68, 82, 83). MAIT cells are distinct from conventional T cells in that 
WKH\FRH[SUHVVWKHWUDQVFULSWLRQDOIDFWRUV(RPHV7EHW525ȖĲDQG+HOLRV84). 
Despite their relatively homogenous phenotype compared to conventional CD8 
T cells, there are subsets of MAIT cells that can be divided based on CD8/CD4 
expression, CD56 expression, and also some level of antigen discrimination based 
RQ7&5ȕFKDLQFRPSRVLWLRQ83)RUH[DPSOHWKHDEXQGDQW9ȕVXEVHWRI
MAIT cells are hyper-responsive to C. albicans stimulation, while MAIT cells 
H[SUHVVLQJ9ȕ9ȕDQG9ȕDUHK\SRUHVSRQVLYHWRE. coli stimulation 
(83). The DN and CD8+ MAIT cell subsets may be functionally distinct, and the 
DN subset may derive from CD8+ MAIT cells. Furthermore, DN MAIT cells have 
a pro-apoptotic gene signature and higher propensity towards activation-induced 
cell death (85). Finally, a subset of MAIT cells express high levels of the NK-cell 
associated molecule CD56 also express more IL-12R and IL-18R on their surface, 
DQGLQWXUQSURGXFHPRUH,)1ȖLQUHVSRQVHWRWKHVHLQQDWHF\WRNLQHVin vitro (86). 
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Figure 3. MAIT cell response to bacterial compared to viral infections. APCs can pre-
sent riboflavin metabolites in the context of MR1 to the MAIT cell TCR, along with CD28 
coreceptor engagement. This can elicit the production of cytolytic effector molecules such 
as GrzB and perforin which can be delivered to target cells. Additionally, TLR, PRR, or 
inflammasome signaling during either bacterial or viral infections can trigger the pro-
duction of inflammatory cytokines such as IL-12 and IL-18 and engage relevant recep-
tors on the MAIT cell surface. Engagement with IL-12 and IL-18 receptors on the MAIT 
cell elicits production of effector cytokines, predominantly IFNȖ. Figure generated with 
information from (87, 88).
1.2.2.1 MAIT cells in viral infections
There is no known viral ligand recognized by MAIT cells, however given that 
0$,7FHOOVFDQSURGXFHWKHDQWLYLUDOF\WRNLQH,)1ȖDQGDUHDOWHUHGGXULQJVHYHUDO
viral infections, their role in viral infections warrants exploring (reviewed in 88). 
There are phenotypic and functional characteristics of MAIT cells that suggest a 
potential role in combating viral infection as well. MAIT cells uniformly express 
IL-18R, and as with NK and other T cell subsets, IL-18 can synergize with IL-12R 
OLJDWLRQWRSURGXFH,)1ȖFigure 3) (89, 90). These innate cytokines can be elicited 
by APCs in the example of a viral infection, through TLR8 binding of viral RNA, 
leading to IL-12 and IL-18 production and supporting a role for MAIT cells in 
antiviral immunity (51, 91). Furthermore, the subset of MAIT cells that express 
CD56 and respond more readily to these innate-like signaling induced by viral 
infections, support a role for MAIT cells in contributing to antiviral immunity (83). 
MAIT cells can also be activated by type-I interferons, molecules produced by a 
wide variety of immune cells and tissue types during viral infections. Stimulation 
ZLWK,)1ĮRU,)1ȕLQFRPELQDWLRQZLWK,/UHVXOWVLQ,)1ȖSURGXFWLRQE\0$,7
cells (92). Type-I interferons can also act as a costimulatory molecule upon MAIT 
TCR engagement, along with other innate signals shown to do the same, including 
71)DQG,/ȕWRJHWKHUZLWK,/93). 
9The impact of MAIT cells in viral infections is emphasized by their changing 
characteristics during acute and chronic viral infections. For example, MAIT fre-
quency and phenotype is altered in humans infected by flaviviruses. Decreased 
MAIT cell frequencies are observed in acute Dengue virus infection, and MAIT 
cells have increased expression of activation markers HLA-DR and CD38 in 
QDWXUDOGHQJXHLQIHFWLRQ0$,7FHOOVZLOODOVRSURGXFH,)1ȖIROORZLQJin vitro 
stimulation of total PBMC with Zika virus. (94). Several studies have observed 
MAIT cell perturbations in chronic HCV infection, where MAIT cells are depleted 
in both the blood and liver. In chronic HCV infection MAIT cells in the blood 
and liver have increased expression of activation and exhaustion markers, with 
hepatic MAIT cells becoming dysfunctional (95). In HIV and HCV co-infection, 
MAIT cells are depleted from the peripheral blood, and therapy is unable to 
restore their loss. However, intrahepatic MAIT cells are restored with therapy in 
HCV monoinfection (96, 97). While MAIT cells are not depleted in HBV, they 
have an increase in activation marker expression (98). Human T-lymphotropic 
virus (HTLV) -1 infection causes depletion and dysfunction in peripheral blood 
MAIT cells as well, and MAIT cell loss is independent of viral load and they do 
not appear to be targets of HTLV-1 infection (99). MAIT cells can be activated 
DQGSURGXFH,)1ȖWKURXJKVWLPXODWLRQin vitro with macrophages or dendritic cells 
infected with dengue virus, Zika virus, influenza, or HCV (92, 94). Activation of 
MAIT cells in this manner depends on IL-12 and IL-18 together, or IL-18 alone. 
In mouse models, MAIT cells also contribute to protection against lethal influenza 
A challenge in a TCR-independent manner (100). 
MAIT cell alterations in chronic HIV monoinfection has been explored in cross-
sectional studies compared to healthy controls, and is reviewed later in this  thesis 
and is the focus of Paper II. Altogether, in vitro work, coupled with observable 
alterations in vivo in viral infection, suggest MAIT cells respond to viral infections.
1.2.3 Invariant natural killer T (iNKT) cells
There are three types of cells commonly referred to as “NKT” cells; Type I, Type II, 
DQG1.OLNH7FHOOV1.OLNH7FHOOVDUHDUHODWLYHO\KHWHURJHQRXVDQGODUJH
population of T cells that are identified generally through the expression of the 
NK-associated markers CD161 or CD56 (101). They are conventional, adaptive 
T cells that recognize antigen using classical MHC molecules (102). True NKT 
cells are an unconventional T cell subset subdivided into Type I and Type II, that 
can recognize and rapidly respond to non-peptide antigens presented in the context 
of the MHC-I-like molecule, CD1d (103). CD1d presents a variety of synthetic, 
exogenous and endogenous glycolipid antigens to the NKT TCR. All CD1 (CD1a, 
b, c and d) molecules present lipid antigen to T cells and are expressed by DCs. 
But only CD1d is expressed by additional cell types including epithelial cells, 
B cells, and macrophages (104). Type I and Type II NKT cell discovery was based 
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on the observation of an unusual phenotypically mature subset of CD4 and CD8 
double negative T cell within the mouse thymus that also expressed the NK-related 
PDUNHU1.DQGSURGXFHWKHF\WRNLQHV,)1ȖDQG,/in vitro (105-107). These 
FHOOW\SHVDOVRKDGELDVHGH[SUHVVLRQRI9ȕ7&5FKDLQ7\SH,,1.7FHOOVKDYH
GLYHUVHĮȕ7&5VDQGDUHRXWVLGHRIWKHVFRSHRIWKLVWKHVLVUHYLHZHGLQUHI108). 
7\SH,1.7FHOOVKRZHYHUKDYHDQLQYDULDQWĮȕ7&5DQGDUHRIWHQFDOOHGLQYDUL-
ant NKT (iNKT) cells, and are a focus of Paper III in this thesis. Engagement 
of the iNKT cell TCR triggers the production of a wide breadth of both TH1 and 
TH2 cytokines, giving them an immunomodulatory role thus far not described 
in MAIT cells. All iNKT cells express the innate-like transcription factor PLZF 
(ZBTB16), a trait they share in common with MAIT cells (109, 110). Like MAIT 
cells, iNKT cells are evolutionarily conserved within mammals, and in humans 
LQYDULDEO\H[SUHVV75$975$-SDLUHGZLWK75%9DVWKHLU7&5ĮDQGȕ
FKDLQVWUDQVODWLQJWR9ĮDQG9ȕDWWKHSURWHLQOHYHO111, 112). The iNKT 
cells can be identified in flow cytometry using monoclonal antibodies against 
WKHLU9ĮDQG9ȕ7&5FRPSRQHQWVDPRQJVW&'7FHOOVLQKXPDQV7KH
V\QWKHWLFPDULQHVSRQJHGHULYHGOLSLGĮJDODFWRV\OFHUDPLGHĮ*DO&HUDQWLJHQ
when loaded into the CD1d molecule, can stimulate iNKT cells. This complex 
also allows for their identification via flow cytometry and further description (113, 
1147KHIUHTXHQF\RIL1.7FHOOVLQKXPDQEORRGLVXVXDOO\YHU\ORZ
RIWRWDO7FHOOVLVYDULDEOHLQWKHOLYHUDQGFDQEHVRPHZKDWHQULFKHG
RI7FHOOVLQWKHJXW115, 116). This low frequency of iNKT cells in the 
blood in humans declines 2 to 10 fold lower in old age (117). Mice have differing 
frequencies compared to humans in the blood and liver, representing between 0.2-
RIWRWDOEORRG7FHOOVEXWRI7FHOOVLQWKHPRXVHOLYHU118). Mouse 
studies have revealed that iNKT cells undergo positive selection by endogenous 
self-ligand presented by CD1d in the thymus (119). 
Phenotypically, iNKT cells in the blood can express NK-associated markers CD161 
and sometimes CD56 and have an effector memory phenotype with expression 
of CD45RO, CCR7, and CD28 (120). Upon activation, iNKT cells can express 
classical markers of T cell activation including HLA-DR and CD38, but they also 
upregulate inhibitory molecules such as PD-1, Tim-3 and LAG-3 (121). iNKT 
cells can be subdivided into CD4+ or CD4- subsets, with distinct phenotypes and 
functional profiles (1227KH&'L1.7FHOOVUHSUHVHQWRIL1.7FHOOV
They are found enriched in the gut mucosa and thymus, and are functionally distinct 
from CD4- iNKT cells, with a bias towards TH2 cytokine production. Considered 
immunomodulatory, CD4+ iNKT can produce IL-4, IL-6, and IL-10, and IL-13 
and are implicated in suppressing the immune response in some mouse disease 
models including diabetes (123). Phenotypically, CD4+ iNKT cells can express 
CD62L giving them lymph node homing capabilities, but can also express tissue-
KRPLQJUHFHSWRUVĮȕ&&5&;&5DQG&&57KH&'L1.7VXEVHWFDQEH
11
GLYLGHGLQWR'1RIL1.7FHOOVRU&'RIL1.7FHOOV124). The 
CD4- subset expresses a wider variety of chemokine receptors including CCR1, 
CCR6, CXCR6 and again, high levels of CXCR4 and CCR5 (122). Amongst the 
CD4- iNKT cells, some express the T cell regulatory transcription factor T-bet and 
produce THF\WRNLQHVOLNH,)1ȖDQG71)DORQJZLWKF\WRWR[LFPROHFXOHVOLNH
perforin and granzyme (125-127). The production of these molecules can occur 
within minutes to hours upon in vitro stimulation (125-127). Others in the CD4- 
L1.7FHOOVXEVHWH[SUHVVWKH525ȖĲWUDQVFULSWLRQIDFWRUDQGKDYHD7H17 functional 
profile with the ability to produce IL-17, IL-21 and IL-22 in vitro. This subset has 
suggested roles in supporting mucosal immunity (127, 128). Additionally, iNKT 
cells can provide B cell help with a TFH (follicular helper) functional profile and 
the expression of follicular homing molecule CXCR5, aiding in the formation of 
early germinal centers in a Bcl-6 dependent manner (129). These TFH iNKT cells are 
predominantly CD4+. In germinal centers, B cells undergo somatic hyper mutation 
and the selection of B cell populations that express high-affinity BCRs to antigen, 
giving rise to mature memory B cells. Finally, all iNKT cells can facilitate direct 
cell to cell killing via FAS/FASL interactions (130).
The antigens loaded into the CD1d molecule that engage the iNKT cell TCR can 
be either endogenously or exogenously derived. The endogenous antigens that have 
been identified include isoglobotrihexosylceramide (iGb3) and ganglioside GD3, 
and there is evidence mammals can produce a-linked glycosylceramides (131-134). 
Exogenous antigens are microbially derived, including a-glucouronosylceramide 
from Bacteroides fragilis, a common inhabitant of the human gut microbiome, and 
bacterial pathogens such as Borrelia burgdoferi, Sphingomonas, and mycobacteria 
(135-138). Despite their small numbers, iNKT cells likely play a role in defend-
ing against microbial pathogens, as they recognize these lipid-derived antigens 
derived from a variety of microbes. However, particular attention has been made 
to TCR-independent activation of iNKT cells through engagement of PAMPs like 
LPS by PRRs expressed by APCs. In response, the APC will produce the innate 
cytokines IL-12 and IL-18 which engage the IL-12R and IL-18R expressed on 
the surface of iNKT cells (139, 140,QUHWXUQL1.7FHOOVZLOOSURGXFH,)1ȖWR
elicit antimicrobial effects against bacterial infections, even if the bacteria cannot 
produce the cognate glycolipid antigen recognized by iNKT cells, such as in the 
case of Salmonella typhimurium (141). Additional research has implicated the 
same mechanism driving iNKT cell activation by fungi, viruses, and protozoa, 
with IL-18 being the dominant cytokine driving this activation, and DCs being the 
dominant APC (142). Interestingly, despite the inability of a pathogen to generate 
cognate lipid antigen to engage the iNKT cell TCR, blocking with CD1d anti bodies 
UHGXFHV,)1ȖSURGXFWLRQin vitro, suggesting a role for TCR engagement in this 
type cytokine-mediated activation. This may depend on the endogenous antigen 
presented by APCs (143). In vivo, infection with microbes in mouse  models has 
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elucidated changes iNKT cell phenotype, function and frequency induced by 
microbial infections. iNKT cells have been found enriched in tissues, such as the 
lung in Cryptococcus neoformans infection, and in the liver of mice infected with 
plasmodium (144, 145). Chronic exposure to microbes in mouse models induces 
an exhausted phenotype in iNKT cells, with an upregulation of PD-1 and hypo-
responsive functionality, followed by apoptosis and sometimes contraction of the 
iNKT cell compartment (146, 147). This suggests that while iNKT cells can be 
rapidly activated to help combat microbial infections, chronic exposure to anti-
gen can lead to an exhausted phenotype, similar to MAIT cells and conventional, 
adaptive T cells.
1.2.3.1 iNKT cells in viral infections
While there have been no viral antigens identified that can be recognized by the 
iNKT cell TCR, iNKT cells can be activated and have indirect roles in viral infec-
tions through differing mechanisms facilitated by APCs (Figure 4). iNKT cell 
activation during viral infection is similar to what is observed in some bacterial 
infections, such as through TCR-independent activation via IL-12R and IL-18R 
engagement. A second mechanism is activation through TCR engagement with an 
endogenous lipid antigen. This type of TCR stimulation is still dependent on IL-12 
and CD40/CD40L costimulation with an APC (Figure 4) (141, 148). Thirdly, LPS 
that enters the blood stream as a consequence of viral infections, such as in HIV 
infection, can cause engagement of TLR4 on APCs and production of the innate 
cytokines that activate iNKT cells (149). 
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Figure 4. Proposed role of iNKT cell help during viral infections. iNKT cells can be 
activated by an APC such as a DC that activates iNKT cells through engagement with 
cytokine receptors on the surface of iNKT cells with or without the TCR engagement with 
an endogenous antigen. IFNȖ production by the activated T cell, along with CD40L engage-
ment can facilitate DC maturation, including the upregulation of CD80/CD86 as well as 
0+&,,RQWKHVXUIDFHRI'&FHOOV'&PDWXUDWLRQFDQDLGLQĮȕ7FHOODFWLYDWLRQDQG
PDWXUDWLRQWRZDUGVYLUXVVSHFLILFUHVSRQVHVIURPĮȕ7FHOOV8SUHJXODWLRQRI&'/RQ
iNKT cells can also provide B cell help, along with IFNȖ and IL-4 production, and allow 
for B cell activation and maturation, thereby eliciting effector antibody responses in leu 
of CD4 helper T cells (150). IFNȖ production by iNKT cells can also activate NK cells, 
thereby eliciting their effector responses. Figure generated with information from (122, 151).
1.2.3.1 iNKT cells in viral infections
To date iNKT cells have been studied in mice in the context of several viral infec-
tions including Lymphocytic choriomeningitis virus (LCMV) and influenza virus. 
LCMV infection causes long-term depletion of iNKT cells from the blood, spleen 
and liver in mice. The mechanism behind this loss may be activation-induced 
13
apoptosis, as remaining iNKT cells have higher expression of caspase 3 (152). In 
influenza A virus models, CD1d knockout mice that lack iNKT cells were more 
susceptible to death from influenza challenge (153). Furthermore,  bronchioalveolar 
ODYDJHIOXLGWKHVHPLFHPHDVXUHGVLJQLILFDQWO\OHVV,)1ȖWKDQLQ:7PLFHFRXSOHG
with less NK-cell activity and antigen-specific CD8+ T cell responses. The influ-
HQ]D$YLUDOLQIHFWLRQPRXVHPRGHOVVXJJHVWWKH,)1ȖSURGXFHGE\L1.7FHOOV
helps CD8 T and NK cells combat viral infection.
The iNKT cell dynamics have also been studied in natural viral infections in 
humans, with studies performed in HIV (reviewed later in this thesis), HCV, and 
influenza virus infected patients. In HCV infection, there are divergent findings 
on iNKT cells. Some studies have shown that iNKT cells are depleted from the 
blood in individuals with detectable viremia compared to healthy controls, and 
iNKT cells found in the liver have an activated phenotype in these individuals 
(154-156). Others have observed similar frequencies of blood iNKT cells in 
HCV infection compared to controls (157). iNKT cells in chronic HCV infection 
may have enhanced ability to produce the TH2 cytokine IL-13 ex vivo compared 
to healthy controls, suggesting iNKT cells could be activated to provide B cell 
help (158). In vitro work with influenza A virus suggests iNKT cells may counter 
the actions of the immunosuppressive cell type myeloid-derived suppressor cells 
(MDSCs), which in the absence of activated iNKT cells suppress the function of 
influenza-specific CD4 and CD8 T cells (159). The important role of iNKT cells in 
viral infections is supported by the concept that certain viruses can downregulate 
and prevent the recycling of the CD1d molecule from the surface of APCs. This 
has been demonstrated in HSV and HIV infection (160, 161), and is a suggested 
mechanism for the evasion of iNKT cell responses in HCV infection (157). 
1.3 The immunodynamics of the mucosal barrier
Mucosal barriers play a major role in innate immunity and act as not only physi-
cal but also immunological barriers. They contain immune cells and tight junc-
tions between lining epithelial cells that protect the host against a vast array of 
microbes that inhabit these locations. Of particular relevance to this thesis is the 
mucosal barrier of the gastrointestinal tract or “gut,” which is populated by a 
commensal microbiota in the healthy state (reviewed extensively elsewhere 162). 
The commensal microbiome can be of benefit to the host, for example the genera-
tion of vitamin K and vitamin B, which humans require for nutrition but cannot 
be metabolize themselves. While maintaining the presence of these beneficial 
commensal microbiota, the gut mucosal barrier must also prevent the invasion of 
these bacteria into the blood and prevent the over proliferation of pathogenic or 
inflammatory bacteria. 
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The gastrointestinal mucosal barrier has several mechanisms to maintain this 
balance. The first is the structure of the tissue itself, with an outer mucous layer 
produced by goblet cells in the intestine. This is underlaid by a border of epi-
thelial cells, followed by the tissue underneath the epithelial layer known as the 
lamina propria. Some lymphocytes reside in the epithelial layer itself. These are 
SUHGRPLQDQWO\&'7FHOOVDQGWKHXQFRQYHQWLRQDO7FHOOVXEVHWȖį7FHOOVZKLFK
are enriched here compared to the blood (163). The lamina propria underlying 
the epithelial layer that lines the gastrointestinal lumen is populated with large 
amounts of immune cells. These immune cells include innate and adaptive popu-
lations such as T cells, B cells, and macrophages. These function to maintain the 
mucosal barrier through cytokine production and the prevention of microbes from 
entering the underlying blood stream. Of relevance to this thesis, it is important to 
note which immune cells participate in maintaining the gut barrier and play a role 
in HIV infection. Unconventional T cells are found in this tissue, including iNKT 
and MAIT cells which play unique roles in the control of invading pathogens. 
CCR5 expressing CD4 T cells are also found in abundance in the gut mucosa and 
display an TEM and TTM phenotype and function (164). IL-17 and IL-22 producing 
cells, such as CD4 T cells and MAIT cells, can also be found in the lamina propria 
and produce the cytokines that assist in maintaining the gut barrier (163). IL-17 
can recruit neutrophils, promote the production of antibacterial molecules known 
as defensins, and induce the proliferation of enterocytes, the epithelial cells lining 
the gastrointestinal lumen (165). IL-22 also promotes enterocytes proliferation, and 
can stimulate the production of mucous by goblet cells (166). It is the maintenance 
of this single layer of epithelial cells and the tight junctions between them that 
prevent the gastrointestinal microbiota from passing into the lamina propria and 
entering the blood stream. Gut homeostasis can be altered, such as when immune 
cells are depleted or altered at this site as a consequence of a viral infection like 
HIV. Such alterations can allow microbes and microbial by products to cross the 
epithelial layer and enter the blood stream to be distributed throughout the body. 
This occurrence is a potential cause of systemic inflammation.
1.4 The immune reponse to HIV infection
From the identification of the virus that causes acquired immunodeficiency syn-
drome (AIDS) in the 1980s, to the introduction of the first antiviral therapy only 
few years later, the scientific community has made monumental advancements 
in patient treatment and life expectancy in those that become infected in a very 
short time (167). However, HIV continues to challenge the minds of researchers 
and clinicians alike (168). The epidemic still rages on in sub-Saharan Africa with 
smaller epicenters in locations like India, Russia and the United States, yet an 
effective preventative vaccine remains elusive (169, 170). Additionally, because 
of the need for complex medical infrastructure, significant financial investment, 
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and the complex societal stigmas that surround effectively treating HIV, a signifi-
cant percentage of those at risk for acquiring or already infected with HIV do not 
have access to treatment (171). Current therapies do not eliminate the latent HIV 
reservoir, wherein circulating viral loads are reduced or undetectable. HIV persists 
in a subset of infected CD4 T cells with limited or undetectable viral replication. 
To add to this, those successfully on treatment continue to be susceptible to seri-
ous non-AIDS events such as cardiovascular disease, malignancies, bacterial and 
fungal co-infections, and sustained immune activation and inflammation (172). 
Furthermore, the ability to reduce the HIV reservoir could signal the beginning 
of an era of HIV cure. These notions drive the need for a cost-effective and effi-
cacious vaccine, and improved therapies for HIV infection. These goals may be 
achievable with a greater understanding of the complex immunological events in 
both the acute and chronic stages of HIV infection (170). 
1.4.1 The immunopathology and T cell response to HIV infection
HIV can be transmitted from an HIV infected individual through semen, vaginal 
secretions, blood, and breast milk. Upon infection, HIV disease progression can 
be divided into three phases: acute HIV infection (AHI), chronic infection (CHI), 
and acquired immunodeficiency syndrome (AIDS). AHI infection occurs in the 
first days to weeks post-HIV transmission. There is first an eclipse phase lasting 
10-12 days post-transmission where HIV RNA is undetectable in the blood with 
current diagnostic testing (173). This is followed by a phase marked by high  levels 
of HIV plasma viremia as the virus replicates, with peak viremia occurring on 
 average 13 days post infection (174, 175). Infected individuals can present with 
acute retrovirus syndrome during this time period, with symptoms such as fever, 
malaise, and lymphadenopathy (175). The primary target of viral infection are the 
CD4 T cells, wherein HIV enters through the binding of the viral envelope protein 
gp120 to the CD4 receptor as well as the coreceptors CCR5 or CXCR4 (176-180). 
The HIV retrovirus enters a host cell as two, single-stranded RNA molecules, capa-
ble of integrating into the host genome. It does this by first by reverse transcribing 
its own viral genome into DNA using the reverse transcriptase enzyme released 
from the infectious virion. The viral cDNA can integrate into the host DNA, pref-
erentially at transcriptionally active sites. Once integrated, HIV then uses the host 
cell transcriptional and translational machinery to generate new infectious virions, 
a process known as productive infection (181). It is widely accepted that HIV-
specific CD4 T cells are the main source of productive infection in HIV, and their 
activation and proliferation provide a transcriptionally active state wherein new 
virions can be produced efficiently (182). Both infected and uninfected mucosal 
CD4 T cells are rapidly reduced in frequency during AHI. An activated CD4 T cell 
that is productively infected may die from the induction of the apoptotic pathway 
facilitated by caspase 3 (183). A resting, abortively infected CD4 T cell likely dies 
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via the inflammatory cell death process, pyroptosis, and may be the fate of the 
PDMRULW\!RILQIHFWHG&'7FHOOV183). In this scenario, the accumulation 
of incomplete reverse transcripts and sensing of viral DNA through IFI16 induces 
formation of the inflammasome and cell death via caspase 1. CD4 T cells can also 
die through the immune response to a virally infected cell or through “bystander” 
induced apoptosis (184-186). However, a percentage of infected CD4 T cells will 
enter the resting phase of the cell cycle and become resting memory CD4 T cells. 
These resting and relatively transcriptionally dormant CD4 T are then considered 
latently infected and are a part of the viral reservoir that escapes both the host 
immune response and antiretroviral therapy (ART) (187-189). Early events in 
AHI define subsequent disease progression, with higher peak viral loads in AHI 
associated with higher viral set point into CHI, establishment of a larger viral 
reservoir, and faster progression to AIDS (190, 191). AHI is likely an ideal time 
for initiation of ART to reduce the size of the viral reservoir, limit inflammation 
and immune activation, and better preserve immunity (191-193). 
Productively infected CD4 T cells disseminate HIV throughout the body. The virus 
initially replicates intensely until peak viral load is observed in the plasma, after 
which it recedes to a set point level approximately 30 days post infection (175). 
In the mucosa, within four days post infection mucosal epithelial cells exposed to 
HIV recruit plasmacytoid dendritic cells (pDCs) to the site of infection. These cell 
initiate the mounting of a cytokine storm. The earliest of these cytokines found 
LQWKHEORRGLQ$+,DUHLQWHUIHURQVVXFKDV,)1ĮLQIODPPDWRU\F\WRNLQHVVXFKDV
,/DQGEHWDFKHPRNLQHVOLNH0,3ĮDQG0,3ȕ194, 195). This cytokine 
milieu recruits other immune cells to the site of infection, such as macrophages 
and T cells, and facilitates a target rich environment of activated CD4 T cells that 
are susceptible to infection and necessary for viral propagation. Subsequently, over 
half of the memory CD4 T cell compartment is depleted, and the HIV-specific 
cytotoxic CD8 T cells expand in response to the infection (Figure 5) (195-197). 
HIV-specific cytotoxic CD8 T cells will control the virus to some extent and 
contribute to establishing viral set point and the beginning of CHI. In most cases, 
HIV escapes away from the host immune response by mutating away from the 
adaptive HIV-specific response, establishing a persistent chronic infection (197, 
198). Due to the persisting virus, CD4 T cell levels continue to decline, and  CD8 
T cells are exposed to chronic antigenic stimulation leading to their functional 
exhaustion into CHI (33, 199). The depletion of the immune system overtime in 
CHI may ultimately lead to the last stage of HIV infection, AIDS. AIDS can be 
defined clinically as a CD4 T cell count below 200 cells/mm, and depletion of 
immune system to this point allows for a number of opportunistic infections. In 
fact, it is the depletion of these essential CD4 helper T cells that leads ultimately 
to immune failure (200, 201). However, with the advancement of effective of 
therapies, individuals on ART may never reach this stage and the associated severe 
immunodeficiency (202).
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In the earliest days of HIV infection, there are dynamic changes within the T cell 
compartment, that continue into CHI and AIDS. Amongst these other T cell subsets 
impacted conventional adaptive CD8 T, MAIT, and iNKT cells, the dynamics of 
which during HIV infection are the focus of this thesis.
1.4.2 The adaptive CD8 T cell response to HIV infection
The exact mechanism of how CD8 T cells control HIV infection is incompletely 
understood, though there is evidence of their contribution to viral control. In most 
who are infected with HIV, the HIV-specific CD8 T cell clonotypes expand in 
coincidence with declining viremia, implicating their role in fighting the virus and 
reducing the viral burden to set point (Figure 5) (197). Viral mutants are able to 
escape the adaptive CD8 T cell response within the first weeks of HIV infection, 
and persist into CHI. This supports the notion that immune pressure from CD8 
T cells is being exerted against the virus (203). Functionally, CD8 T cells may be 
controlling virus through either cytotoxic or soluble factor- mediated  mechanisms, 
or a combination of both. HIV-specific CD8 T cells ability to produce perforin and 
Grz directly ex vivo is higher in individuals that are able to spontaneously control 
virus, supporting a role for CD8 T cell cytotoxic functionality in controlling HIV 
replication (204). HIV control may also be established by CD8 T cells through the 
DELOLW\WRSURGXFHVROXEOHIDFWRUVLQFOXGLQJWKHEHWDFKHPRNLQHV5$17(60,3Į
DQG0,3ȕ205). These are molecules that prevent the entry of R5-tropic HIV 
into a target cell. The production of beta chemokines from CD8 T cells can limit 
viral replication in vitro and also correlates with individuals able to spontaneous 
control virus (206, 207). 
The CD8 T cells that persist in HIV infection exhibit an exhausted phenotype, 
with upregulation of markers of activation such as HLA-DR and CD38 as well as 
exhaustion markers PD-1 and TIM-3 (208, 209). The expression of these markers 
in CHI is accompanied by impairment of CD8 T cytotoxic capacity and cytokine 
production, and reduced ability to proliferate (33, 210). The cause of this pheno-
type and function likely has several contributing mechanisms. One possible cause 
is chronic antigenic stimulation for HIV-specific CD8 T cells, driven by persis-
tent viral replication and the absence of help from the depleted CD4 T cell com-
partment (211$VPDQ\DVRIFLUFXODWLQJ&'7FHOOVDUH+,9VSHFLILFLQ
untreated individuals, contributing to a large pool of CD8 T cell that may become 
exhausted in this manner (212). Bystander activation may also drive exhaustion 
and functional decline in adaptive CD8 T cells during HIV infection. This TCR-
independent stimulation is facilitated through the engagement of chemokine and 
cytokine receptors expressed by CD8 T cells (213). While the exact mechanism of 
TCR-independent CD8 T cell activation and exhaustion in HIV infection has yet 
to be determined, peak CD8 T cell activation correlates with peak type-I interferon 
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levels in the plasma during the course of infection, suggesting a role for type-I 
interferons as a contributor of CD8 T cell activation (214). Non-HIV specific CD8 
T cells may be activated in this manner in CHI. Elevated expression of HLA-DR 
and CD38 is observed on CD8 T cells specific for Epstein bar virus, cytomeg-
alovirus, and influenza A virus from HIV infected individuals (213). In chronic 
untreated and treated HIV infection the CD4:CD8 ratio remains low (Figure 5), 
suggesting there are elevated levels of CD8 T cells beyond those of HIV-specific 
clonotypes. A third possible cause of adaptive CD8 T cell altered phenotype and 
functionality in CHI is chronic immune activation, propelled by the decline in gut 
integrity and introduction of microbial products into the peripheral blood (24, 197, 
215, 216). The presence of LPS and other markers of microbial translocation in 
the blood can activate APCs to produce activating cytokines that lead to CD8 T 
cell activation. The role of microbial translocation in HIV infection is reviewed 
in more detail later in this thesis. 
Figure 5. Numerical, phenotypic, and functional changes in conventional CD8 T cells 
in acute and into chronic, treated HIV infection. Dynamics of conventional CD8 and 
CD4 T cells in HIV infection, with rapid decline of CD4 T cells in acute infection and their 
reconstitution upon ART initiation. CD8 T cells expand in response to the viral burden, 
become activated, and maintain that level of activation to some extent even with ART ini-
tiation. ART initiation also restores CD8 functionality to some extent, albeit not the same 
levels as pre-infection. Material from: Perdomo-Celis, Taborda and Rugeles, CD8+ T-Cell 
Response to HIV Infection in the Era of Antiretroviral Therapy, Frontiers in Immunology, 
2019, Frontiers Journal Series.
In most cases HIV is unable to be completely controlled by the adaptive CD8 
T cell response as the infection progresses, leading to a rise of inefficient and 
exhausted CD8 T cells and advancement to AIDS (33, 199, 203, 217, 218). The 
exceptions where individuals can spontaneously control HIV are referred to as 
“HIV controllers.” These individuals were initially shown to have enrichment of 
an MHC-I encoding allele, HLA-B*57 (219). It is thought that this allele, similar 
to other protective alleles like HLA-B*27 and HLA-B*14, presents viral epitopes 
that mount a more effective HIV-specific CD8 T cell response (219, 220). CD8 
T cells in controllers maintain higher levels of cytolytic effector molecules, have 
a great ability to proliferate, and demonstrate higher polyfunctionality, or the 
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ability to produce multiple cytokines in response to in vitro stimulation, than non-
controllers (221-225). The antigenic target of the HIV-specific CD8 T cells also 
appears to play a role in spontaneous viral control. Individuals with early adaptive 
CD8 T cell responses directed towards the HIV Gag protein are more likely to be 
controllers (226, 227). Several in vitro studies also suggest that in controllers, the 
HIV-specific CD8 T cells are more cross-reactive, meaning they can recognize a 
broader array of antigens compared to non-controllers (228). Despite the poten-
tial for CD8 T cell control, the overwhelming majority of the time, HIV is able 
to escape the adaptive immune pressure from CD8 T cells and persist in the host. 
In another chronic viral infection where CD8 T cells become exhausted, HCV 
infection, many individuals are unable to clear the virus, thought in part due to 
impaired CD8 T cell function and viral escape away from the HCV-specific CD8 
T cell response (229, 230). An anomalous CD8 T cell phenotype was observed 
LQFKURQLF+&9LQIHFWLRQZLWKDVLJQLILFDQWO\KLJKHUSURSRUWLRQRIĮȕ&'7FHOO
H[SUHVVLQJ)FȖ5,,,$&')FȖ5,,,$LVDUHFHSWRUWKDWELQGVWKH)FSRUWLRQ
of antibodies and is associated with antibody-dependent cellular cytotoxicity 
$'&&)FȖ5,,,$LVDORZDIILQLW\)FUHFHSWRUPHDQLQJWKDWELQGLQJZLOORFFXU
only if there is a large amount of antibody present, such as the opsonization of 
a cell (231:KHQDQHIIHFWRUFHOOH[SUHVVLQJ)FȖ5,,,$HQJDJHVWKHH[SRVHG)F
SRUWLRQRIDERXQGDQWLERG\RQDWDUJHWFHOO)FȖ5,,,$DFWLYDWHVWKHHIIHFWRUFHOO
to deliver cytotoxic molecules like granzymes to kill the target cell (232). This 
function and receptor expression are usually attributed to NK cells, but can be 
H[SUHVVHGLQRWKHUFHOOW\SHVLQFOXGLQJQHXWURSKLOVPRQRF\WHVDQGȖį7FHOOV233-
236)FȖ5,,,$H[SUHVVLQJ&'7FHOOVLQFKURQLF+&9LQIHFWLRQKDYHDWHUPLQDO
effector phenotype, and functionally respond in a manner similar to that of NK 
cells upon CD16 stimulation, with robust degranulation after in vitro stimulation 
(237). This suggests that CD16+ CD8 T cells may contribute to the immune con-
trol of the virus by ADCC through an unexpected mechanism. ADCC is a critical 
function in HIV infection, as ADCC responses in adults are associated with slower 
disease progression (238, 239). Furthermore, HIV negative infants born to HIV 
positive mothers have evidence of passive acquisition of HIV-specific, ADCC-
mediating antibodies. This same study showed that in infants that do become 
infected, higher levels of HIV-specific ADCC mediating antibodies correlated 
with reduced infant mortality (240). Importantly, in the RV144 HIV vaccine trial 
ADCC-mediating IgG was associated with decreased acquisition of HIV (241). 
+RZHYHUWKHUROHRIWKHH[SUHVVLRQRI$'&&PHGLDWLQJ)FȖ5,,,$RQ&'7
cells has yet to be elucidated in CHI. Therefore, a cohort of chronically infected, 
untreated individuals from the Rakai District of Uganda was used to survey for the 
H[SUHVVLRQRI)FȖ5,,,$RQ&'7FHOOVLQPaper IV of this thesis (Figure 8). The 
DELOLW\RI)FȖ5,,,$H[SUHVVLQJ&'7FHOOVWRPHGLDWH$'&&WKHLUSKHQRW\SH
and their transcriptional signature was also examined.
20
1.4.3 The MAIT cell response to HIV infection
Although it has not been shown that MAIT cells can recognize HIV antigen or 
be infected with HIV, perturbations in MAIT cells in cross sectional studies show 
that MAIT cells are altered during HIV infection. MAIT cells are lost permanently 
in the periphery and remaining MAIT cells are dysfunctional in CHI (73, 242). 
Studies of SIV infection in nonhuman primates (NHP) show similar findings of 
numerical decline in the blood. These studies also show fewer MAIT cell in the 
lymph nodes and broncho-alveolar lavage fluid compared to uninfected NHPs (243). 
This loss may contribute to weakened mucosal immunity and the susceptibility 
of chronically infected individuals to fungal and bacterial co-infections such as 
tuberculosis, non-typhoidal Salmonella, and Streptococcus pneumoniae infections 
(244-247). As TB is a common and sometimes deadly coinfection of the lung in 
those infected with HIV, studying the implication of declining MAIT cells to the 
susceptibility to TB is of great interest as MAIT cells can be found in the lung 
mucosa. MAIT cells in chronic HIV/TB co-infection are severely affected as in 
HIV monoinfection, but MAIT depletion is not seen in the periphery in TB mono-
infection, suggesting HIV as the driver of MAIT cell decline (248). Furthermore, 
MAIT cells are enriched in bronchio-alveolar lavage fluizd in individuals with 
active tuberculosis (301). Several cross-sectional studies of CHI have observed 
activation and dysfunctionality in MAIT cells in tissues other than the peripheral 
blood, such as the lymph nodes and gut mucosa, compared to healthy controls 
(73, 242, 249). It was initially thought that the MAIT cell loss observed in CHI 
was due to the downregulation of CD161 on the MAIT cell surface, but use of the 
5-OP-RU loaded MR1 tetramer confirmed the numerical loss of MAIT cells in the 
blood (242, 250). Still, loss of CD161 expression is a contributing factor to this 
pattern in patients with late stage chronic HIV infection (66). The residual MAIT 
cell population circulating in chronic untreated HIV infection express markers of 
activation , HLA-DR, CD69, CD38, and PD-1 (73, 84, 242). They also express 
higher levels of tissue-homing markers compared to uninfected controls such as 
CCR5, CCR6, CCR9, and CXCR6, suggesting MAIT cells may be recruited to sites 
of inflammation during HIV infection. Work with NHP models further elucidated 
WKDWSHULSKHUDOEORRG0$,7FHOOVXSUHJXODWHWKHJXWKRPLQJPDUNHUĮȕZLWKLQ
3 weeks post SIV/SHIV infection. This, coupled with increased expression of 
proliferation marker Ki-67 and the expanded frequency of MAIT cells in the gut, 
suggested that loss of MAIT cells in the blood may be in part due to trafficking 
to the gut (251). Because mucosal barrier homeostasis and integrity is markedly 
disrupted during HIV infection, MAIT cells may be recruited to sites of bacterial 
infiltration in the mucosa in order to combat the rising microbial burdens. This 
prolonged activation of MAIT cells at these sites may ultimately cause their demise 
due to activation-induced apoptosis (73, 252). 
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Functionally, MAIT cells from chronically HIV infection individuals have reduced 
DELOLW\WRSURGXFH,)1Ȗ71)DQG,/DDIWHUPLOGO\IL[HGE. coli stimulation, in 
vitro (253). This functional decline is not observed in early HIV infection when 
MAIT cells are stimulated in vitro with the strong MAIT cell antigen 5-OP-RU 
(four months post-infection) (250). However, several years of ART partially restores 
WKHDELOLW\RISHULSKHUDO0$,7FHOOVWRSURGXFH,/DDQG,)1ȖEXWZDVXQDEOHWR
diminish the expression of PD-1 (242). Recently, single-cell transcriptomic work 
showed a large upregulation of IFN-induced genes in MAIT cells in HIV infected 
LQGLYLGXDOV7KHVDPHVWXG\GHPRQVWUDWHGWKDWVXVWDLQHG,)1ĮVLJQDOLQJLQGXFHG
IL-10 production in monocytes, which in turn reduced IL-12 signaling, a power-
ful costimulatory molecule for MAIT cell functionality. This ultimately inhibited 
the MAIT cell response to E. coli stimulation in vitro, suggesting a mechanism 
contributing to diminished MAIT cell function in chronic HIV infection (254). The 
cytokine IL-7, which is thought to be necessary for T cell memory, may contribute 
to enhanced MAIT cell function. Short stimulation with IL-7 induces cytolytic 
“arming” of MAIT cells in vitro (84). IL-7 is reduced in the blood in CHI, and 
administration as an HIV treatment may reduce the HIV reservoir (84, 255). In a 
small pilot study of HIV infected individuals on ART, administration of IL-7 was 
able to partially restore circulating frequencies of MAIT cells, suggesting IL-7 
treatment may alleviate circulating MAIT cell loss (256). However, the effect of 
IL-7 administration systemically, especially in mucosal sites where MAIT cells 
may have their most important role, has not been determined. The exact cause and 
temporal dynamics of the loss, activation, and ultimate functional exhaustion of 
MAIT cells in HIV infection is unknown.
Because of the proposed role that MAIT cells play in combatting bacterial coinfec-
tions, and because they are irreversibly lost in the blood and to some extent the 
gut in HIV infection, this thesis aims in part to understand the temporal dynamics 
of MAIT cells in AHI (Paper II). Using a unique, prospective cohort from the 
U.S. Military HIV Research Program (MHRP) with cryopreserved blood samples 
from donor-matched, pre- and post-HIV infection time points captured within the 
first days of infection (Figure 6), the temporal dynamics of MAIT cells in AHI 
can be examined (175). 
1.4.4 The iNKT cell response to HIV infection
As with MAIT cells, iNKT are reduced in frequency in the blood in HIV infection. 
In fact, CD4 expressing iNKT cells and are preferentially depleted from the blood 
compared to conventional CD4 T cells (257-259). However, the mechanism of 
decline for iNKT cells is likely different than that of MAIT cells. In two landmark 
studies by Sandberg et al. and Motsinger et al. in 2002, iNKT cells were shown to 
be preferential targets of HIV infection in vitro (257, 258). Given that iNKT cells 
express high levels of the HIV entry coreceptors CCR5 and CXCR4 alongside 
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the CD4 molecule, and are preferentially infected over conventional CD4 T cells, 
iNKT cells may play a significant role in viral seeding, propagation of the founder 
virus, and establishment of latent HIV reservoirs. 
The CD4+ subset of iNKT cells is depleted faster than their CD4 negative counter-
parts during HIV infection, suggesting that they may be depleted by different 
mechanisms. HIV viral load measurements correlate inversely with the CD4+ iNKT 
cell counts and percentages, while the CD4 negative subset does not (257, 258). 
In NHPs, it was not only shown that iNKT cells decline in frequency and can be 
infected with SIV, but in a monkey species that lacks CD4+ iNKT cells, there is 
no iNKT cell depletion in SIV infection compared to healthy controls (257, 260). 
In the gut mucosa, CD4+ iNKT cells are more prevalent compared to the blood, 
but are depleted in individuals with CHI compared to healthy controls (261). Loss 
of gut, but not peripheral blood, CD4+ iNKT cells correlates with T cell activation 
and viral load, suggesting a link to disease progression. Furthermore, in individu-
als on therapy and thus undetectable viremia, CD4+ iNKT cells were found to 
be depleted in the blood but not in the gut mucosa (262). This is an interesting 
finding, and it may be that initiation of ART begins the trafficking of CD4+ iNKT 
cell from the blood into the gut, allowing for replenishment of their numbers in 
this tissue and not the peripheral blood (251). These authors also discovered that 
elite controllers had higher frequencies of iNKT cells in their gut mucosa that 
non-controllers, including those on therapy. This may suggest that natural control 
of HIV viremia prevents the loss of CD4+ iNKT cells in the gut. As the majority 
of iNKT cells in the gut express CD4 and produce TH2 cytokines such as IL-4 
and IL-10, the authors propose that the immunoregulatory role of these persisting 
iNKT cells suppress the immune activation and microbial translocation normally 
observed in HIV. Supporting this, the ability of gut iNKT cells from HIV infected 
people to produce IL-4 and IL-10 after PMA/ionomycin stimulation in vitro cor-
related inversely with CD4 and CD8 T cell activation. Along these lines, amount 
of IL-4 produced by iNKT cells in vitro correlated inversely with levels of marker 
of microbial translocation, LPS-binding protein, in the plasma. 
Another case motivating further understanding iNKT cell dynamics in HIV infec-
tion involves the HIV proteins Nef and Vpu. Nef and Vpu downregulate a variety 
of host cell surface molecules, including MHC-I, in order to evade the immune 
response to viral antigen presentation. HIV can downregulate CD1d on the surface 
of APCs by interfering with its recycling from endosomal compartments (161). 
Thus, HIV has a mechanism to directly evade iNKT cell responses. Furthermore, 
iNKT cells can recognize HIV-infected DCs through a TCR-mediated mechanism 
(263). It has yet to be determined if iNKT cells are infected with HIV in vivo, 
which is one of the goals of Paper III of this thesis. In Paper III the temporal 
dynamics of iNKT cell depletion in the blood and gut mucosa in untreated and 
early treated HIV infection is explored, as well as the effects of AHI on iNKT 
cell phenotype, function, and gene expression profile in the blood. These analyses 
23
were performed with the same cryopreserved blood samples from unique cohort 
of natural HIV infection as in Paper II, as well as an additional cohort of patients 
where ART was initiated in AHI from Thai donors using cryopreserved blood and 
fresh gut biopsy samples (Figures 6 and 7). 
1.4.5 Disruption of the gut mucosal barrier in HIV infection and 
associated microbial translocation 
Studies in NHPs illuminate how rapid depletion of gut-associated CD4 T cells in 
acute SIV infection through direct infection with SIV, or bystander cell death by 
the apoptosis of nearby cells that are either infected or uninfected, leads to a per-
manently altered balance of the gut barrier (196, 264). It is thought that the loss of 
IL-17 producing CD4 T cells is particularly devastating to the epithelial layer, as this 
cytokine and thus the cells that produce it are critical for enterocyte proliferation 
and maintenance. IL-17 producing CD4 T cells are also slow to recover after ART 
initiation (265). HIV infection also causes dysregulation of the gut microbiome, 
with declining representation of commensal bacteria and increasing frequency in 
more inflammatory bacterial species, even upon ART initiation (266). Finally, there 
is disruption of tight junctions between epithelial cells in the gut in HIV infection, 
and HIV proteins themselves may facilitate this disruption. The HIV proteins Tat 
and gp120 can be released from infected CD4 T cells and have been implicated 
in the disruption of tight junctions in the gastrointestinal tract (267, 268). This is 
facilitated through the aberrant internalization and sometimes proteasomal degra-
dation of surface proteins involved in tight junction formation after induction of 
the mitogen- activated  protein kinase (MAPK) pathway in epithelial cells (269). 
Additionally, proinflammatory cyto kines released from epithelial cells and gut 
DVVRFLDWHGLPPXQHFHOOVLQFOXGLQJ71)FDQVWLPXODWH1)ț%VLJQDOLQJLQGXFLQJ
actin cytoskeleton contraction and downregulate expression of proteins involved 
in tight junction formation between epithelial cells, as well (270). Observations 
of damaged and inflamed gut epithelia and lamina propria are observed even 
upon ART initiation in the acute stages of HIV infection, albeit the inflammation 
is somewhat ameliorated after treatment initiation. Furthermore, ART initiation 
in acute HIV has been shown to preserve IL-17 producing CD4 T cells in the 
gut (286). However even upon ART initiation in AHI, a biomarker of enterocyte 
turnover, intestinal fatty-acid binding protein (I-FABP), and marker of monocyte 
activation and microbial translocation, soluble CD14 (sCD14), remains elevated 
above healthy control levels (271). With or without ART,  damage to this critical 
component of the immune system occurs during HIV infection and facilitates 
microbial translocation, or the translocation of microbial products from the lumen 
of the intestine into the bloodstream and driving systemic immune activation (272).
Systemic immune activation in HIV is marked by sustained levels of inflammatory 
VROXEOHIDFWRUVLQWKHEORRGVXFKDV,)1ĮDQG7*)ȕSRO\FORQDO%FHOODFWLYDWLRQ
T cell activation, and a high turnover of CD4 and CD8 T cells (273-276). This leads 
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to both T cell exhaustion and the generation of new targets for HIV infection. The 
presence of microbial products in the blood stream is systemic and is observed even 
in ART treated individuals with durably suppressed viral loads (272, 277). When 
gastrointestinal microflora translocate into the lamina propria of the gut in a healthy 
state, they are rapidly phagocytosed by the host immune cells (278). However, in 
HIV infection there is dysregulation of the immune cell homeostasis in the lamina 
propria, and thus translocated microbes and microbial by products make their way 
into the blood and can even persist within the body at extraintestinal sites (279). 
LPS is a component of the cell wall in gram-negative bacteria and a TLR4 agonist 
as previously mentioned, and is most well studied in dendritic cell and macrophage 
activation (280). Initial studies of microbial translocation in HIV reported LPS 
levels elevated in the blood in CHI compared to uninfected controls (272). LPS 
OHYHOVFRUUHODWHGZLWKVROXEOHPDUNHUVRILQQDWHLPPXQHDFWLYDWLRQLQFOXGLQJ,)1Į
In vitro work in this study showed the induction of sCD14 expression from LPS-
stimulated monocytes. In a somewhat disputed conclusion, the authors argue that 
sCD14 can act as a surrogate biomarker of microbial translocation. LPS can bind 
CD14 when bound to LPS-binding protein (LBP), another surrogate biomarker 
for microbial translocation produced in the liver. The LPS-LBP complex binds to 
CD14-expressing Kupffer cells, or liver-resident macrophages, which in turn shed 
their CD14 molecules (281). This hypothesis that sCD14 is exclusively a marker of 
microbial translocation is disputed by the notion that monocytes can be activated 
DQGSURGXFHV&'WKURXJKLQQDWHF\WRNLQHVWLPXODWLRQVXFKDVZLWK,)1ĮZKLFK
is also elevated in the blood during chronic HIV infection (282). Whether or not 
sCD14 is a true marker of microbial translocation, its elevated levels in chronic HIV 
infection coupled with elevated levels of LBP, EndoCAb (endotoxin-specific IgG), 
LPS, and I-FABP in circulation strongly suggests that microbial translocation is 
occurring and influencing the immune response  during chronic HIV infection (283). 
Additionally, Brenchley et al. found that LPS levels in the blood in CHI correlate 
with CD8 T cell activation measured as the coexpression of CD38 and HLA-DR, 
suggesting microbial translocation-induced immune activation can be a driver of 
the sustained CD8 T cell activation observed in HIV infection. Another marker of 
immune activation is C-reactive protein (CRP), and is a reliable marker of disease 
progression (284). It is produced is mainly from the liver, although IL-6 produced 
from monocytes can also cause the vascular endothelium to release this soluble 
IDFWRU,)1ȖLQGXFLEOHSURWHLQ,3LVDOVRDVROXEOHPDUNHURILPPXQHDFWL-
vation associated with HIV infection, and is a chemokine released from a variety 
RIFHOOW\SHVLQFOXGLQJO\PSKRF\WHVLQUHVSRQVHWR,)1ȖVLJQDOLQJ285). Sustained 
immune activation is thought to a leading cause of non-AIDS related co-morbidities 
like HIV-associated neuro cognitive disease (HAND), cardiovascular disease, and 
liver and renal disease (172). Additionally, sustained immune activation and the 
increased microbial presence in the periphery may be a driver of the MAIT and 
iNKT cell depletion and activation observed in chronic HIV infection studies, the 
temporal dynamics of which are aims in Paper II and III of this thesis.
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2 AIMS
Initially, the goal of this thesis was to gain an understanding of the unknown 
immunodynamics of MAIT cells in AHI. To do this, an optimized flow  cytometry 
panel was required to identify and sort for MAIT cells. The iNKT cell markers 
were also included in this flow cytometry panel to enhance the use of a precious 
cohort of natural HIV infection. Exploration of these unconventional and innate-
like T cells in HIV infection added motivation to complete an unfinished story 
about an innate-like conventional CD8 T cell subset, also in the context of HIV. 
Therefore the aims of this these are as follows: 
1. Develop a flow cytometry panel to identify conventional and unconventional 
T cells and markers of activation on their surface to maximize use of a precious 
longitudinal cohort in HIV infection.
2. Determine the phenotypic, functional, and transcriptional changes in peripheral 
MAIT cells during AHI and define drivers of any observed changes such as 
correlations to viral load or markers of microbial translocation.
3. Determine the phenotypic, functional, and transcriptional changes in peripheral 
and colonic iNKT cells during AHI and upon ART initiation during AHI.
4. Examine for the presence of a unique, innate-like CD8 T cells in chronic, 
untreated HIV infection and define their functional relevance in HIV.
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3 METHODS
3.1 Ethics
All subjects in studies RV217/WRAIR#1373, RV254/SEARCH 010/ WRAIR#1494, 
and RV304/SEARCH 013/WRAIR#1751, were adults and provided written 
informed consent. For subjects that were unable to read, the consent document was 
read to them with an impartial witness present; the volunteer, the witness and the 
study staff obtaining consent signed the affidavit with a signature or mark. Studies 
were reviewed and approved by the human subject ethics and safety committees in 
each country, as well as by the Walter Reed Army Institute of Research (WRAIR) 
(Silver Spring, MD, USA), in compliance with relevant federal guidelines and 
institutional policies. RV304: The Institutional Review Board of the Faculty of 
Medicine, Chulalongkorn University; and the WRAIR Institutional Review Board. 
RV217: Institutional Review Board Royal Thai Army Medical Department; Kenya 
Medical Research Institute (KEMRI) Scientific and Ethics Review Unit (SERU); 
Uganda National HIV/AIDS Research Committee (NARC); Mbeya Medical 
Research and Ethics Committee (MMREC) and the National Health Research Ethics 
Committee (NatHREC); and the WRAIR Institutional Review Board. RV254: The 
Institutional Review Board of the Faculty of Medicine, Chulalongkorn University; 
and the WRAIR Institutional Review Board.
The RV228 Rakai District cohort was approved by the following institutional 
review boards in the United States and Uganda: the institutional Review Boards 
of Uganda’s National Council for Science and Technology and the National AIDS 
Research Committee, as well as Division of Human Subjects Protection at the 
Walter Reed Army Institute of Research. All participants gave written informed 
consent. For samples from the Couples Observational Study (COS) in Kampala, 
Uganda, all participants gave written-informed consent, and ethical approvals for the 
study were obtained from Uganda’s National Council for Science and Technology 
and the National AIDS Research Committee and the University of Washington.
3.2 Subjects
3.2.1 The RV217 Early Capture HIV Cohort study (ECHO)
To investigate MAIT and iNKT cell dynamics in AHI, longitudinal samples from 
29 individuals were available for the study of MAIT cells (Paper II), and 23 over-
lapping individuals for the study of iNKT cells (Paper III) in AHI. These indi-
viduals were enrolled in a unique U.S. Military HIV Research Program (MHRP) 
cohort, as previously described (175). Briefly, consenting, HIV uninfected adults 
at high-risk for acquiring HIV were enrolled in this prospective trial to study HIV 
incidences rates and viral load dynamics in AHI in three countries in East Africa 
and Thailand (Figure 6). HIV uninfected participants had lifestyle  qualifications 
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for enrollment, with women exchanging goods for sex as the predominant  enrollees 
in East African countries, and men who have sex with men (MSM) as the pre-
dominant enrollees in Thailand. Enrollees were educated on HIV prevention and 
given access to providers for infection treatment, based on national guidelines. 
Participants were screened bi-weekly for the presence of HIV RNA in the plasma 
using the Real-Time HIV Assay (m2000 Real Time System, Abbott Molecular), 
and if HIV was detected, were entered in a second phase of study where follow 
up visits collected larger blood volumes in order to study the immunodynamics 
of AHI. Cyropreserved PBMC were used with donor-matched pre-infection and 
at least 3 post-HIV infection time points, with time points ranging from 1–1,040 
days post first positive test for HIV RNA. The majority of the data about iNKT 
and MAIT cell dynamics in AHI in this thesis come from time points coinciding 
with peak viral load (VL) (median 16 days, range 14–22, since first positive test 
for HIV RNA), set point VL (median 43 days, range 31–50, since first positive test 
for HIV RNA), and early chronic infection (median 85 days, range 60–126, since 
first positive test for HIV RNA (Figure 6)). 
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Figure 6. The RV217 Early Capture HIV Cohort (ECHO). Samples from the RV217 
cohort were used to study MAIT and iNKT cell dynamics in acute HIV infection. This study 
enrolled high-risk, consenting adults at four clinical research sites: Walter Reed Project, 
Kericho, Kenya; Makerere University Walter Reed Project, Kampala, Uganda; Mbeya 
Medical Research Center, Mbeya, Tanzania; and Armed Forces Research Institute of Medical 
Sciences, Bangkok, Thailand. 
3.2.2 The RV254/SEARCH 010 early ART initiation, and the RV304 
uninfected control cohorts
RV254 is a currently ongoing study in Bangkok, Thailand that enrolls acutely HIV 
infected individuals in order to study the effects of ART initiation in the acute stages 
of HIV infection, wherein ART is initiated a median of 4 days from cohort enroll-
ment (Figure 7). For Paper III, cryopreserved PBMC were used to study iNKT 
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cell frequency, phenotype, and functionality in the blood, with samples from 40 
donors after ART initiated during AHI. Rectosigmoid colon biopsies collected by 
sigmoidoscopy from RV254 participants were used to study MAIT and iNKT cell 
frequency in the colon in acute, untreated HIV infection. In total, 26 donors from 
RV254 participating in elective rectosigmoid biopsies at any time during diagno-
sis, and from 20 donors followed up after 24 months of treatment, were collected 
to study iNKT cell phenotype in AHI and after treatment initiation in the colon 
(Paper III). Of the acutely HIV infected donors from the RV254 cohort, samples 
from 7 were used to study MAIT cell frequencies in the colon before ART initia-
tion (Paper II). Rectosigmoid colon biopsies from 17 uninfected age- sex- and 
risk- matched uninfected controls from the RV304/SEARCH 013 study were used 
to compare MAIT cell frequency in HIV uninfected controls (Paper II), whereas 
samples from 28 donors were used to study colonic iNKT cell frequency and 
phenotype as uninfected controls.
Figure 7. The RV254 early ART initiation cohort. Donors with acute HIV infection from 
Thailand were used to study the immunodynamics of ART initiated in the acute stages of 
HIV infection. Cryopreserved PBMC and rectosigmoid colon biopsies from the RV254 
cohort were used to study the effect of treatment initiation on iNKT cells in acute HIV 
infection before and after treatment. Rectosigmoid colon biopsies were used to study MAIT 
cell frequencies in untreated, acute HIV infection. 
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3.2.2.1 Biopsy processing and calculation of absolute number of colonic T-cell 
subset
RV254 or RV304 subjects underwent a routine sigmoidoscopy procedure under 
moderate conscious sedation. Approximately 30 endoscopic biopsies were ran-
domly collected from the sigmoid colon using Radial Jaw 3 biopsy forceps (Boston 
Scientific, Natick, MA, USA), with 20–25 processed for flow cytometry analysis 
within 30 minutes of collection, as previously described (286). Cell counts were 
performed manually by Trypan Blue exclusion, which allows exclusion of epi-
thelial cells due to morphological differences compared to lymphocytes. Absolute 
numbers of conventional CD4 T, iNKT, and MAIT cells per gram of gut tissue 
were calculated by multiplying the total viable lymphocyte count by frequencies 
of cell subsets obtained from flow cytometric analysis. The total lymphocyte 
count per gram of tissue was calculated by dividing the viable lymphocyte count 
by  tissue weight. This proportion was then multiplied by the percent of cells in the 
live lymphocyte gate and that number was subsequently multiplied by the percent 
of T cells. The absolute number of colonic T cells was used in conjunction with 
the subset percentages to determine the absolute number of each T cell subset per 
gram of biopsy tissue.
3.2.3 The RV228 chronic untreated HIV infection cohort
Donors with chronic, untreated HIV infection and community-matched  uninfected 
controls were used to both optimize performance of OMIP-046 (Paper I) and exam-
LQHWKHSUHYDOHQFHRI)FȖ5,,,$&'7FHOOVLQ&+,Paper IV). Study participants 
aged 15–49 years old were enrolled in a prospective community-based cohort to 
assess the prevalence and incidence of HIV infection in Rakai District of Uganda, 
from 1998 to 2004 (Figure 8) (41–43). The Rakai District borders Lake Victoria and 
is largely a fishing district with a high incidence of HIV infection, predominantly 
in women who exchange goods for sex (287-289). Infected and enrolled subjects 
had continued annual follow up through 2008. Blood samples from 103 randomly 
selected HIV seropositive individuals and 40 community-matched seronegative 
controls were obtained. PBMCs were isolated and cryopreserved as described 
previously (290). None of the patients had received ART. The HIV–infected study 
participants initiating ART were from the Couples Observation Study (COS) in 
Kampala Uganda as previously described (291). 32 HIV-infected partners in each 
HIV–serodiscordant couple was followed up after the initiation of ART. Samples 
were collected; CD4 T cell counts determined and viral load assessments made at 
baseline, 6 and 12 months after initiation of ART. 
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Figure 8. The RV228 chronic untreated HIV infection cohort to study the prevalence of 
)FȖ5,,,$H[SUHVVLQJ&'7FHOOV Cryopreserved PBMC from the Rakai District, Uganda 
were used to determine the frequency, phenotype, function, and transcriptional signature 
of FcȖRIIIA-expressing CD8 T cells in chronic, untreated HIV infection. Samples from 
the Kayunga District were used to determine the frequency of FcȖRIIIA-expressing CD8 
T cells pre- and post-antiretroviral treatment.
3.3 Polychromatic flow cytometry
Polychromatic flow cytometry panels were used to measure MAIT, iNKT, and 
conventional CD8 T cell phenotype, function, and for cell sorting for down-
stream transcriptomics. The panels can be found in detail in Paper I, II, III and 
IV. Briefly, cryopreserved samples were thawed in pre-warmed media, washed, 
stained with LIVE/DEAD Fixable Aqua Dead Cell dye (ThermoFisher), blocked 
for Fc receptors using normal mouse serum (ThermoFisher), and surface stained 
with antibody cocktail. Samples were surface stained at room temperature for 
30 minutes, and some were intracellularly stained using BD Perm/Wash Buffer (BD 
Biosciences) at room temperature for 30 minutes. For assessment of transcription 
factors, cells were washed, permeabilized and fixed using an optimized kit (FOXP3 
transcription factor staining buffer set) before intranuclear stain. Some samples 
ZHUHIL[HGLQSDUDIRUPDOGHK\GHRU%'),;3(50%XIIHU%'%LRVFLHQFHV
before acquisition on a 5 laser, 16-parameter BD LSRII SORP flow cytometer 
(BD Biosciences) within 12 hours of staining. Other samples used for sorting for 
downstream transcriptomics were resuspended in sorting buffer (PBS containing 
%6$DQGVRUWHGIRUHLWKHU51$6HTWDUJHWHGPXOWLSOH[HG57T3&5ZLWK
Fluidigm Biomark, or the functional PanToxiLux Assay. Data were analyzed with 
FlowJo v.9.9.4 (TreeStar). Flow cytometry data were acquired with a BD LSR 
II instrument or a BD FACSCanto II instrument (BD Biosciences). Sorting was 
performed on a 5-laser BD FACSAria II SORP (BD Biosciences) contained in a 
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biosafety cabinet. Clinical lymphocyte immunophenotyping was performed using 
the FACS MultiSET System and run on a FACSCalibur using the single-platform 
Multitest four-color reagent in combination with Trucount tubes (BD Biosciences).
3.3.1 Multiplexed targeted quantitative gene expression analysis 
(RT-qPCR) 
To study gene expression changes in MAIT cells in AHI, CD161bright9Į
MAIT cells from 20 individuals from the RV217 acute capture cohort from one 
pre-infection and three post-infection time points were bulk sorted (100 cells/well) 
directly into reaction mixture (SuperScript III Reverse Transcriptase/Platinum Taq 
Mix, Cells Direct 2X Reaction Mix, Invitrogen) into a 96 well plate (Paper II). 
The same was done for three sorted T cell populations and CD56dim CD3- NK cells 
from 8 donors from the RV228 Rakai District chronic HIV infection cohort to 
VWXG\JHQHH[SUHVVLRQLQ)FȖ5,,,$H[SUHVVLQJ&'7FHOOVFHOOVZHOO
(Paper IV51$IURPEXONVRUWHG9ȕ9ĮL1.7FHOOVIURPRQHSUHDQG
two post-infection time points was used from 10 donors from the RV217 cohort 
to study gene expression in iNKT cells in AHI (Paper III). Targeted genes evalu-
ated for each cell type can be found in detail in Paper II , III, and IV. Briefly, 
reverse transcription and specific transcript amplification were performed using 
a thermocycler (Applied Biosystems Gene Amp PCR System 9700) with the fol-
lowing parameters: 50 °C for 15 minutes, 95 °C for 2 minutes, and 95 °C for 15 
seconds; and then 60 °C for 30 seconds for 18 cycles. Amplified cDNA was then 
loaded into a Biomark 96.96 Dynamic Array chip using the Nanoflex IFC control-
ler (Fluidigm). This microfluidic platform was then used to conduct quantitative 
PCR (qPCR). Threshold cycle (CT), as a measurement of relative fluorescence 
intensity, was extracted from the BioMark Real-Time PCR Analysis software. 
3.3.2 RNA-seq analysis
In Paper II, peripheral blood MAIT cells identified as CD161bright9ĮZHUH
purified by sorting (range of 1911–64,011 cells) using a FACS Aria SORP (BD 
%LRVFLHQFHVSHOOHWHGDQGRYHUODLGZLWKȝORI51$ODWHU7KHUPR)LVKHUDQG
IUR]HQDWí&6HTXHQFLQJZDVSHUIRUPHGDW681<0ROHFXODU$QDO\VLV&RUH
RNA was extracted using the RNeasy Mini Kit (Qiagen), and RNA quality and 
concentration were assessed with the Agilent 2100 Bioanalyzer Pico Chip. RNA-
Seq libraries were prepared using the SMART-Seq v4 Ultra Low Input RNA Kit 
(Clontech) according to the manufacturer’s instructions. Amplified material was 
purified using Agencourt AMPure XP beads (Beckman). cDNA quantity was 
assessed on a Qubit 3.0 (ThermoFisher) and fragment size was evaluated on a 2100 
BioAnalyzer (Agilent). The PCR products were next indexed using the Nextera 
XT DNA Library Prep Kit (Illumina) according to the manufacturer’s instructions. 
Briefly, products were tagmented using the Amplicon tagment mix containing Tn5 
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transposase and indexed using Nextera index 1 (i7) and index 2 (i5) primers. The 
libraries were again cleaned-up with Agencourt AMPure XP beads, quantified, 
pooled, and sequenced across 75 base pairs (bp) using a single-end strategy with 
a 75-cycle high output flow cell on a NextSeq 500 (Illumina). Nine biological 
replicates were sequenced, with four donor-matched time points corresponding to 
one pre-infection and three post HIV-infection time points at peak viral load, set 
point viral load, and early chronic infection. Median reads per  sample was 22.9 
million. The Unix based program Spliced Transcripts Alignment to a Reference 
(STAR) v.2.6.1 with human genome hg38 was used for alignment, and transcription 
mapping was performed using RNA-seq by Expectation Maximization (RSEM) 
v.1.3.155 (292, 293). The feature Counts program was used for counting mapped 
reads. RUVSeq v1.12 was used to remove unwanted variation and differentially 
expressed gene list was generated by edgeR v3.20. R package (294, 295). The 
GSEA method as used for finding statistically significant pathways with 5,917 
gene sets of GO in Molecular Signatures Database (MSigDB) issued by Broad 
Institute (296). 
3.4 Functional assays
3.4.1 iNKT and MAIT cell functionality measured in vitro
MAIT and iNKT cell functionality were assessed using one of three stimulation 
techniques (Paper II and III). PBMC were stimulated for 24 hours with briefly 
fixed E. coli (D21) together with anti-CD28, or for 24 hours with rhIL-12 and 
rhIL-18, or for 6 hours with PMA/ionomycin as the manufacturer described 
(eBioscience™ Cell Stimulation Cocktail (500X), ThermoFisher). All conditions 
included BFA and monensin for the last 6 hours of stimulation and were stained 
for flowy cytometry for markers of degranulation and intracellular cytokines.
3.4.2 PanToxiLux Assay to measure ADCC
In Paper IV, measurement of ADCC was performed using the PanToxiLux assay 
(OncoImmunin, Gaithersburg, MD) similar to previously described (297). rHIV 
BaL gp120 (catalog no. 4961; obtained through the National Institutes of Health 
AIDS Reagent Program, Division of AIDS, National Institute of Allergy and 
Infectious Diseases, National Institutes of Health) were used to coat target CEM.
NKRCCR5 cells, which are resistant to spontaneous NK cell lysis. After coating CEM.
NKRCCR5WDUJHWFHOOVZLWKJSLQ)%6±530,PHGLDFHOOVZHUHODEHOHG
with a fluorescent target cell marker, TFL4 (OncoImmunin), for 15  minutes at 37°C 
DQG&22. Cells were washed twice with PBS and stained with LIVE/DEAD 
Fixable Aqua Dead Cell Stain (Life Technologies) for viability for 30  minutes 
DW57$IWHUZDVKLQJLQ)%6±530,PHGLDFHOOVZHUHUHVXVSHQGHGWRD
concentration of 8.0 x 105 cells/ml. Sorted effector cell populations (NK cells, 
33
CD45RA+CD57+ CD8 T cells, and CD45RA-CD57- CD8 T cells) were washed 
LQ)%6±530,PHGLDDQGUHVXVSHQGHGWRDILQDOFRQFHQWUDWLRQRI[6 
FHOOVPOIRUDQ(7UDWLRRI,QDZHOOSRO\SURS\OHQHSODWHȝORIERWK
WDUJHWDQGHIIHFWRUFHOOVXVSHQVLRQVZHUHERWKDGGHGWRZHOOVDORQJZLWKȝO
of the granzyme B substrate (OncoImmunin). After incubation for 5 minutes at 
URRPWHPSHUDWXUHȝORI+,9,J1RUWK$PHULFDQ%LRORJLFDOV0LDPL)/DW
DȝJPOZDVDGGHGDQGWKHSODWHZDVLQFXEDWHGIRUDQRWKHUPLQXWHVDW
room temperature. The plate was then spun at 300xg for 1 minutes and incubated 
DW&DQG&22 for 1 hour. After washing cells were acquired on an LSR 
II SORP (BD Biosciences) on the same day. Fluorophores were detected using 
a 488-nm 50-mW laser with 515/20 filters to detect the granzyme B substrate, a 
406-nm 100-mW laser with 525/50 filters to detect Aqua LIVE/DEAD stain, and 
a 640-nm 40-mW laser with 670/30 filters to detect TFL4 target cell stain. Data 
were analyzed by using FlowJo 9.7.5 (Ashland, OR).
3.5 Soluble cytokine analysis
Luminex® bead based detection assays were used to measure plasma levels of 
CRP and IL-6 (EMD Millipore, Billerica MA) per manufacturer’s instructions. 
Samples were mixed with a cocktail of MagPlex® magnetic microspheres bound 
to capture antibody specific to proteins of interest. After incubation with the sample 
overnight at 4 °C, excess sample was washed away using a magnetic plate washer 
(BioTek Instruments, Winooski VT). Biotinylated detection antibody cocktail was 
added for 1 hour at RT. Streptavidin-phycoerythrin was added for 30 minutes before 
a final wash and resuspension in sheath fluid. Data was collected on a FlexMap 
3D® system. Levels of sCD14 and I-FABP were measured by chemiluminescent 
detection ELISA (R&D Systems, Minneapolis MN) per manufacturer’s instruc-
tions and read on a VersaMax® reader (Molecular Devices, Sunnyvale CA). Data 
were analyzed in Prism version 6.0 for Mac OS X (GraphPad, La Jolla CA) using 
a 4-parameter fit standard curve.
3.6 Statistical analyses
The Wilcoxon Signed Rank test was used for comparison of non-parametrically 
distributed paired data sets. Unpaired data was analyzed using the Mann–Whitney 
test, and the Spearman rank correlation test was used to compare correlation between 
two parameters. For matched longitudinal analysis a nonparametric Friedman test 
was performed with the Dunn’s multiple comparison test. Statistical analyses were 
performed with GraphPad Prism v.6.0c (GraphPad Software). *p<0.05, **p<0.01, 
***p<0.001
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4 RESULTS
4.1 An optimized multiparameter flow cytometry 
panel (OMIP-046) to identify conventional and 
unconventional T cells and surface expression 
of markers of activation and exhaustion 
Because of the unique nature of the cohorts used in this thesis, it was essential 
that the methods used were optimized to maximize use of precious cohorts with 
longitudinal sampling before and after untreated, AHI. In particular, the nature of 
the cohort is invaluable given that current protocol of HIV treatment now recom-
mends beginning ART upon diagnosis. Being able to study the immunodynamics 
of natural, untreated HIV infection is a gift and therefore every precaution was 
taken to ensure that no samples were wasted or under-utilized. The dynamics of 
unconventional T cells in acute, untreated HIV infection has yet to be explored in 
this setting, therefore the first step was to design a flow cytometric panel to meas-
ure the frequency and phenotype of conventional and unconventional T cells. This 
panel was designed to be compatible with FACS sorting, with the goal of sorting 
several cell subsets for downstream gene expression analysis. Thus, in Paper I, 
a 14-color flow cytometric panel was designed to identify conventional, adaptive 
CD8 and CD4 T cells, as well as iNKT and MAIT cells (Figure 9a and b). Cell 
surface expression of T cell activation markers HLA-DR and CD38, and markers 
of T cell exhaustion PD-1 and TIGIT were measured on each of these four subsets, 
with particular attention paid to the unconventional T cell subsets (Figure 9c). 
Although the initial goal of this thesis was to determine MAIT cell dynamics in 
AHI as in Paper II, the ability to have similar data for iNKT cells was beneficial 
and primed additional studies, resulting in Paper III. 
Using OMIP-046, the relative baseline frequencies of MAIT cells and iNKT 
cells in HIV uninfected individuals could be determined (Figure 10). As MAIT 
FHOOVDQGL1.7FHOOVFDQUHSUHVHQWDQ\ZKHUHIURPRURISHULSKHUDO
T cells, respectively, establishing baseline frequencies of these variable T cell sub-
sets between geographic locations outside of HIV infection was important. This 
information is essential to interpret subtle changes in frequencies in donors from 
different regions post HIV-infection.
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

)LJXUH8QFRQYHQWLRQDODQGFRQYHQWLRQDO7FHOOVDQGWKHH[SUHVVLRQRIPDUNHUVRI
7FHOODFWLYDWLRQDQGH[KDXVWLRQFDQEHLGHQWLILHGXVLQJ20,3 a) Example  gating 
strategy to identify T cells from cryopreserved PBMC from a chronically infected, HIV 
positive donor. b) Identification of the four T cell populations of interest, convention 
CD4 T cells (green), conventional CD8 T cells (purple), MAIT cells (red) and iNKT cells 
(orange). c) Example staining of markers of T cell activation HLA-DR and CD38 mark-
ers of exhaustion PD-1 and TIGIT on the surface of the unconventional T cell subsets. 
Reproduced with permission from (298).
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)LJXUH20,3FDQLGHQWLI\WKHUHODWLYHIUHTXHQF\RIXQFRQYHQWLRQDO7FHOOVXE
sets in HIV uninfected donors in the U.S., and in East African and Thai donors from 
the RV217 cohort. Unconventional T cell subsets were identified in cryopreserved PBMC 
from uninfected U.S. based donors and compared to the frequencies of pre-HIV infection 
time points in donors from East Africa and Thailand in the RV217 cohort.
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Interestingly, compared to HIV uninfected U.S. donors, HIV uninfected individu-
als from East Africa had lower frequencies of MAIT cells but higher frequencies 
of iNKT cells in the peripheral blood. Uninfected Thai donors had comparable 
levels of MAIT cells compared to the U.S. donors, but higher levels of iNKT cells. 
The reasons underlying the differences between unconventional T cell frequencies 
between geographical locations is beyond the scope of this thesis, however genetic 
and environmental factors could play a role in determining unconventional T cell 
frequencies in the blood. 
4.2 MAIT cells expand in the blood and the gut in acute 
HIV infection
After optimizing OMIP-046, the panel was used to study MAIT cell frequency 
and phenotype in AHI (Figure 11a). This was done using cryopreserved PBMC 
from the RV217 cohort, with longitudinal samples of natural HIV infection from 
pre- and post-HIV infection time points in AHI from donors from East Africa and 
Thailand (Paper II, Supp. Table 1) (Figure 6). In analysis of one pre-infection 
time point and donor matched post- HIV infection time points ranging from a 
median of 14 days post first test for HIV RNA out to 3 years post-infection, it was 
determined that the MAIT cell frequency is relatively unchanged compared to pre-
infection within the acute infection stage (Figure 11b). This was surprising, given 
that previous research using cross-sectional studies would suggest that the MAIT 
cell loss observed in CHI may occur within the acute infection time frame. Data 
generated from the RV217 cohort suggests that the loss occurs later than these 
studies hypothesized. However, the absolute count of MAIT cells revealed dynamic 
changes within the MAIT cell compartment in the blood in AHI. A brief period of 
MAIT cell expansion was observed at the time point corresponding to a median 
of 43 days post-HIV infection, around VL set point, with return to pre-infection 
levels later in infection (Figure 11c and Figure 19). Using an additional cohort, 
RV254, in which rectosigmoid colon biopsies from acutely infected individuals 
were collected (Paper II, Supp. Table 2), an expansion of the absolute cell count 
of MAIT cells was also observed in the colon (Figure 11d). As detailed earlier in 
this thesis, the T cell compartment is incredibly dynamic during AHI. Therefore, 
normalized values of T cell abundance are critical measurements for understanding 
their perturbations during this time period. Taken together, the overall MAIT cell 
count expands in both the blood and colonic gut mucosa in AHI. In donors where 
follow up samples were available out to 3 years post-infection, overall MAIT cell 
frequency began to decline, consistent with observations of MAIT cell decline 
observed in cross sectional studies of chronic HIV infection (Figure 11b). 
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)LJXUH0$,7FHOOVH[SDQGLQWKHEORRGDQGJXWLQDFXWHLQIHFWLRQ+,9LQIHFWLRQD) MAIT 
cells were identified as CD161bright9ĮDPRQJVW7FHOOVLQFU\RSUHVHUYHG3%0&XVLQJ20,3
046 on donors from the RV217 cohort. b) The frequency of MAIT cells was determined in longitu-
dinal samples from pre-infection and into AHI. c) Absolute counts of MAIT cells  comparing 1 day 
post first positive test for HIV RNA and 43 days post first positive test for HIV RNA, the time point 
corresponding to set point VL in the RV217 cohort. d) The normalized MAIT cell count per gram 
of tissue in recto-sigmoid biopsies in uninfected control group compared to HIV infected donors 
in acute infection. Material from: Lal et al., Dynamic MAIT cell response with progressively 
enhanced innateness during acute HIV-1 infection, Nature Communications, 2019, Nature Research.
4.3 MAIT cells have an activated phenotype and gene 
expression profile, and enhanced functional  capacity 
in acute HIV infection
The data set generated with OMIP-046 was also interrogated for the expression of 
markers of activation and exhaustion measured on the surface of MAIT cells within 
AHI from the RV217 cohort. At the first measured time point post-infection, corre-
sponding to peak VL, MAIT cells express significantly higher levels of T cell acti-
vation markers HLA-DR and CD38. They also express higher  levels of markers of 
T cell exhaustion, the check point inhibitors PD-1 and TIGIT (Paper II, Figure 2a). 
In MAIT cells sorted based on the OMIP-046 panel for targeted multi plexed gene 
expression analysis (RT-qPCR), markers of activation and exhaustion were also 
elevated at the transcript level (Paper II, Figure 2b). Expression of these markers 
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correlated with the gene encoding Ki-67 (MKI67) at the post-infection time point 
corresponding to peak VL (Paper II, Figure 2d), suggesting activation induced 
cell proliferation. Induction of MAIT cell proliferation due to activation at peak 
VL may indicate why there is an increase in MAIT cell levels a few weeks later 
at the time of set point viral load (Figure 19). Increased expression of markers of 
activation and exhaustion is observed in MAIT cells throughout AHI, and out to 
3 months post- infection. 
MAIT cells in the blood are dysfunctional in chronic HIV infection compared to 
healthy controls, but the timing of the onset of this dysfunction is unknown. Therefore, 
MAIT cell functionality was explored through in vitro stimulation of RV217 samples. 
Total PBMC were stimulated with either mildly fixed E. coli or PMA/ionomycin, 
DQGH[SUHVVLRQRIPDUNHUVRIF\WRWR[LFLW\&'DDQG*U]%RUF\WRNLQH,)1ȖDQG
TNF) produced by MAIT cells was analyzed (Paper II, Figure 6a-c). MAIT cells 
displayed a brief boost in functional capacity at the time point corresponding to set 
point VL, driven by enhanced CD107a and GrzB production after E. coli stimulation 
(Paper II, Figure 6d). However, at the time point corresponding to early, chronic 
infection (3 months post-infection) MAIT cells showed declining functional capac-
LW\FRPSDUHGWRSUHLQIHFWLRQZLWKORZHUHGDELOLW\WRSURGXFH,)1ȖDQG71)DIWHU
PMA/ionomycin stimulation, possibly marking the beginning of the dysfunctionality 
observed in MAIT cells in chronic HIV infection (Paper II, Figure 6d).
Taken all together, MAIT cells become activated as early as peak VL in AHI, and 
this may lead to activation-induced cell proliferation, the consequence of which 
is measured a few weeks later with an increase in MAIT cell counts in the blood 
and colon. MAIT cell activation may in turn induce a boost in functional  capacity, 
measured at set point VL. MAIT cells may be exhausted as a consequence of acti-
vation and functional boost early on, given that their decline in functional capacity 
is observed by 3 months post-infection.
4.4 MAIT cell activation and function correlate with 
markers of microbial translocation and innate 
immune activation
To further understand what drives MAIT cell activation and functional changes 
in AHI, MAIT cell activation and function were correlated with soluble factors in 
the plasma that correspond to innate immune activation and markers of microbial 
translocation. As MAIT cells have a proposed protective role at the gut mucosa, 
and their loss in chronic HIV infection may contribute to sustained immune acti-
vation and microbial translocation, MAIT cells could be associated with markers 
of these events in AHI. Measurements of soluble factors in the plasma in AHI 
show peak levels of marker of innate immune activation CRP at peak VL, with 
gradual and moderately elevated levels of sCD14 and I-FABP within the acute 
infection stage (Paper II, Figure 7a). IL-6 had gradually rising levels, with the 
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highest observed at set point VL. The peak of MAIT cell activation, observed at 
peak VL (median days post first positive test for HIV RNA = 14), correlated with 
sCD14 levels at the same time point (Paper II, Figure 7b). Likewise, the peak of 
MAIT cell function, observed at viral set point (median days since first positive 
test for HIV RNA = 43), correlated with levels of sCD14, also at the same time 
point (Paper II, Figure 7b). Further analysis revealed that CRP levels at peak VL 
(median day since first positive test for HIV RNA = 16), where CRP levels are 
highest, can predict MAIT cell functionality at later time points in acute HIV, cor-
UHODWLQJSRVLWLYHO\ZLWK71)DQG,)1ȖH[SUHVVLRQE\0$,7FHOOVDWVHWSRLQW9/
(median day since first positive test for HIV RNA= 43) and early chronic infection 
(median days since first positive test for HIV RNA = 85) (Paper II, Figure 7c). 
These data suggest that systemic immune activation and microbial translocation 
may be contributing to perturbations in MAIT cell function and phenotype in AHI.
4.5 In acute HIV infection MAIT cells become more 
innate-like phenotypically, functionally, and 
transcriptionally
The altered gene expression in MAIT cells in AHI measured by targeted multiplexed 
RT-qPCR motivated a deep dive into changing gene expression patterns induced by 
AHI in MAIT cells. Therefore, RNA-seq was performed on bulk sorted CD161bright 
9Į0$,7FHOOVIURPQLQHGRQRUVIURPSUHLQIHFWLRQWLPHSRLQWDQGSRVW
infection infection time points in AHI. RNA-seq revealed a large upregulation of 
genes at the post-infection time point compared to pre-infection, corresponding 
to peak VL, with a trend towards normalized gene expression profile by the time 
point corresponding to early chronic infection (Figure 12a). When these differ-
entially expressed genes in AHI were subjected to Gene Set Enrichment Analysis 
(GSEA), a pathway entitled Natural Killer cell mediated immunity was found to 
be upregulated in MAIT cells (Figure 12b). Further analysis from the targeted 
multiplexed gene expression data on MAIT cells also revealed the upregulation of 
a large number of genes normally attributed to NK cells, such as NCAM1, KLRD1, 
NKG7, IL12RB1, and IL18R1 (Figure 12c). Taken together, MAIT cells in AHI 
are skewed towards an innate transcriptional profile compared to pre-infection. 
An innate-like MAIT cell phenotype was next explored, motivated by previous 
research that identified a subset of MAIT cells that expresses CD56 (NCAM-1), a 
cell surface protein that is also often associated with NK cells (83). CD56+ MAIT 
cells express elevated levels of IL-12R and IL-18R on their surface and produce 
PRUH,)1ȖLQUHVSRQVHWRVWLPXODWLRQZLWKWKHLQQDWHF\WRNLQHV,/DQG,/in 
vitro compared to their CD56- counterparts. This pattern was confirmed in RV217 
uninfected controls (Figure 12e). In AHI, MAIT cells expressing CD56 expanded 
overtime, with the largest increase observed at the last available time point out 
to 3 years post infection (Figure 12d). Stimulation of pre- and post-HIV infec-
tion time points in vitro revealed a maintenance of the ability of both CD56- and 
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CD56+ MAIT cells to respond to IL-12 and IL-18 stimulation in vitro post-HIV 
infection. This is counter to what is observed with other means of MAIT cell 
stimulation, where MAIT cells have declining functional responses at the same 
time point into early, chronic infection in response to PMA/ionomycin or E. coli 
stimulation (median days since first positive test for HIV RNA=85) (Paper II, 
Figure 6d). These data suggest an enhancement of innate-like gene expression, 
phenotypic, and functional profile in MAIT cells in AHI.
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and functionality in acute HIV infection. a) The upregulated (red) and down regulated 
(blue) genes in three post-infection time points in AHI are compared to pre-infection in 
bulk sorted CD161bright VĮ7.2+ MAIT cells subjected to RNA-seq. b) Enrichment plot of 
an upregulated gene signature after GSEA of bulk sorted MAIT cell RNA-seq data. c) 
Differential expression of genes associated with innate immunity post-HIV infection com-
pared to pre-infection after targeted, multiplexed gene expression analysis of sorted MAIT 
cells. d) Concatenation of protein expression of CD56 in MAIT cells from all samples and 
time points pre and post-HIV infection. e) Example staining of IFNȖ expression in MAIT cells 
and CD56 MAIT cell subsets after IL-12 and IL-18 stimulation in vitro, and (f) the amount 
of IFNȖ produced by MAIT cells in acute HIV infection in both CD56- and CD56+ MAIT 
cells. Material from: Lal et al., Dynamic MAIT cell response with progressively enhanced 
innateness during acute HIV-1 infection, Nature Communications, 2019, Nature Research.
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4.6 Rapid and preferential activation, dysfunction, and 
decline of CD4+ iNKT cells in the acute stages of 
HIV infection
The other unconventional T cell subset whose identifying markers were included in 
the flow cytometry panel included in the OMIP-046, the iNKT cells, was examined 
next (Figure 13a). Using some of the same overlapping donors in RV217 where 
MAIT cell dynamics was measured, the temporal dynamics of iNKT frequency, 
phenotype, function and gene expression was explored (Paper III, Table 1). 
There was a significant decline in the frequency (Figure 13b) and absolute counts 
(Figure 19) of blood iNKT cells at the first post-infection time point corresponding 
to peak VL in AHI. The relative depletion of CD4+ iNKT cells at this time point 
was more substantial than that of conventional CD4 T cells (Figure 19). As it is 
thought that the CD4- and CD4+ iNKT cell subsets differ in several respects in 
the healthy host and in their susceptibility to death in HIV infection. Therefore, 
determining factors driving both CD4- and CD4+ iNKT cells loss is important. 
The CD4+ subset declined at a faster rate and more robustly than CD4- iNKT cells, 
supporting differing causes of their loss in the blood (Figure 13 c and d). In fact, 
CD4+ iNKT cells may be directly infected early and play a role in establishing 
viral replication in the acute infection stage, as pre-infection levels of iNKT cells, 
and more strikingly CD4+ iNKT cells, correlate with peak VL post-infection in 
AHI (Paper III, Figure 3c-e). 
The expression of markers of T cell activation and exhaustion were also meas-
ured on iNKT cells in AHI. iNKT cells expressed elevated levels of the activation 
makers CD38 and HLA-DR, but not of markers of exhaustion PD-1 and TIGIT, 
at the time point corresponding to peak VL (Figure 13e). Additionally, iNKT 
cell functionality was measured after PBMC from RV217 were stimulated with 
PMA/ionomycin. Here, it was elucidated that iNKT cell dysfunction observed in 
CHI may begin in AHI, with declining ability of iNKT cells to produce TNF and 
,)1Ȗin vitro by approximately 3 months post-infection (Figure 13g). Bulk sorted 
iNKT cells from AHI also showed altered gene expression profiles compared to 
pre-infection as determined by targeted multiplexed RT-qPCR. iNKT cells post-
infection upregulated genes marking T cell activation such as the chemokines CCL4 
and CCL3, and LAG3 which encodes an inhibitor protein in T cells (Paper III, 
Figure 2). Additionally IFI16, a marker of pyroptosis, the pathway thought to 
drive HIV-infected conventional CD4 T cell death, was upregulated in iNKT cells 
at peak VL (Paper III, Figure 2). 
42












	

  
0 25 50 75
0
1
2
3
%
 o
f i
N
K
T 
ce
lls
 
CD38 TIGITHLA-DR* *
***
**
**
*
Days since 1st positive test for HIV-1 RNA
)LJXUHL1.7FHOOVGHFOLQHLQIUHTXHQF\EHFRPHDFWLYDWHGDQGG\VIXQFWLRQDOLQDFXWH
HIV infection. a) Representative staining of iNKT cells and their expression of CD4 amongst 
living T cells. b) Total iNKT cells, (c) CD4+ iNKT cell subset and (d) CD4- iNKT cell 
subset frequencies in acute HIV infection amongst T cells, the VL is shown in red and the 
median overtime is shown in blue. e) The median expression overtime of CD38, HLA-DR, 
and TIGIT on iNKT cells in acute HIV infection, and the (f and g) expression of cytokines 
by iNKT cells after stimulation in vitro with PMA/ionomycin.
4.7 ART initiation in acute HIV infection prevents iNKT 
cell loss in the blood, but not in the gut
The RV217 acute capture cohort demonstrated that iNKT cells rapidly decline 
in acute untreated HIV infection, and previous research has shown this loss is 
not fully recovered upon ART initiation in chronic HIV infection. The impact of 
initiating ART in AHI on iNKT cell dynamics, at a time when most individuals 
are unaware they are infected with HIV, is unknown. To address this, samples 
from RV254, a cohort where ART is initiated in AHI, were utilized and compared 
to community-matched controls (Paper III, Table 2). Donors were categorized 
based on Fiebig stages (I-III). Unlike untreated HIV infection, ART initiation 
during the acute stage prevented iNKT cell decline in the blood 24 months post-
ART, even in the highly susceptible CD4+ iNKT cells (Figure 14a). There was 
also no detectable change in the expression of markers of activation HLA-DR, 
CD38, or TIGIT in iNKT cells compared to uninfected controls 24 months post 
43
ART initiation (Figure 14b)LQDOO\WKHDPRXQWRI71)DQG,)1ȖSURGXFHGE\
blood iNKT cells in vitro after PMA/ionomycin stimulation was similar to that 
of uninfected controls (Figure 14c). This promising result gives incentives for 
early treatment initiation, as peripheral blood iNKT cells in acute, treated HIV 
infection are preserved.

 
Figure 14. ART initiation in acute HIV infection prevents iNKT cell loss, activation, and 
dysfunction in the blood. a) Total iNKT cell frequency or the CD4+ iNKT subset in HIV 
negative donor-matched subjects compared to acutely infected, HIV+ untreated donors 
and 24 months post-ART initiation. b) Expression of HLA-DR, CD38 and TIGIT in HIV 
uninfected controls compared to 24 months after ART initiated in acute HIV infection. 
c) Cytokine expression in iNKT cells in HIV uninfected controls compared to 24 months 
after ART initiated in acute HIV infection after stimulation with PMA/ionomycin in vitro.
Despite the breadth of knowledge that can be gained using peripheral blood 
sampling, the real battle in HIV infection occurs in the gut mucosa. iNKT cells 
are inhabitants of the gut, and possible targets of HIV infection. Therefore, their 
dynamics in this location are essential to understanding their role in HIV seed-
ing, pathogenesis, and the progression to AIDS. Sigmoid colon biopsies from the 
RV254 acute treatment initiation cohort and uninfected matched controls from 
the RV304 cohort were used to study iNKT cells in the colon. Prior to treatment 
in AHI, donors already had significantly lower counts of iNKT cells per gram of 
tissue in the colon compared to uninfected controls (Figure 15a). This reduction 
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was most pronounced in the CD4+ iNKT cells subset (Figure 15b and c). Donors 
that received 24 months of ART initiated in AHI still had lower levels of colonic 
iNKT cells compared to healthy controls. Prior to treatment in acute HIV infection, 
the plasma VL correlated negatively to the number of CD4+, but not CD4-, iNKT 
cells in the colon (Figure 15d and e). Depletion of colonic CD4+ iNKT cells was 
also more severe than that of conventional CD4+ T cells at this site, with more 
pronounced relative depletion compared to healthy controls before (Figure 15f) 
and after treatment (Figure 15g). Levels of CD4+ iNKT cells in the gut also cor-
related negatively with levels of soluble factor and marker of immune activation 
IP-10 in the plasma. This suggests that the depletion of the immunomodulatory 
CD4+ iNKT cell subset from the colon may be a partial contributor to systemic 
immune activation. (Paper III, Figure 8a).
Figure 15. Early ART initiation does not prevent the rapid and preferential depletion of 
iNKT cells in the colon. a) Total iNKT cells, (b) the CD4+ iNKT cell and (c) CD4- iNKT 
cell subsets per gram of tissue in recto-sigmoid colon biopsies in uninfected controls com-
pared to untreated, HIV infected donors in acute infection and 24-month post ART initiation 
in acute infection. The plasma viral load at time of biopsy sampling in untreated, acutely 
infected individuals correlated with the (d) CD4+ iNKT cell subset, and (e) CD4- iNKT 
cell subset. The relative fold change of the depletion of conventional CD4+ T cells and 
the CD4+ iNKT cell subset (f) pre-ART initiation, and (g) after 24 months on ART initi-
ated in acute HIV infection.
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4.8 Chronic untreated HIV infection leads to the 
 emergence of a terminal effector, innate-like 
&'7FHOOVXEVHWWKDWH[SUHVVHV)FȖ5,,,$
After exploring innate-like, unconventional T cells in AHI, it seemed like a plau-
sible hypothesis that in CHI, chronic activation of conventional adaptive CD8 
T cells through persistent antigen exposure and systemic inflammation could lead 
to an altered, possibly innate-like properties in conventional T cells. Toward that 
end, cryopreserved PBMC from a cohort of chronically infected, untreated HIV+ 
donors from the Rakai District of Uganda were used to explore the prevalence of 
)FȖ5,,,$&'H[SUHVVLRQLQFRQYHQWLRQDO&'7FHOOV7KLVSRSXODWLRQKDV
previously been observed in chronic HCV infection (237). The function of CD16 
is often studied in the NK cells and can facilitate ADCC. In this cohort there was 
DVLJQLILFDQWLQFUHDVHLQ)FȖ5,,,$H[SUHVVLQJ&'7FHOOVLQFKURQLF+,9LQIHF-
tion compared to uninfected controls (Figure 16a and b). This expanded subset 
expressed higher levels of the marker of T cell activation, CD38, but not the 
immune checkpoint inhibitor PD-1, suggesting they may not be exhausted compared 
their CD16-negative counterparts, and retain some functional capacity (Figure 
16a, c, and d). This was supported by elevated levels of the cytolytic effector 
molecule perforin in CD16+ CD8 T cells compared to CD16- (Paper IV, Figure 
2c). Further exploration of their phenotype revealed that CD8 T cells expressing 
)FȖ5,,,$LQ&+,H[SUHVV&'5$DQG&'EXWQRW&&5RU&'DSKHQRW\SH
consistent with terminally differentiated effector memory T cells re-expressing 
CD45RA (TEMRA) (Table 1) (Paper IV, Figure 2a, b, and c). Expression of the 
activating and inhibitor receptors killer Ig-like receptors (KIRs) was also evalu-
ated on CD16+ CD8 T cells and compared to their CD16- counterparts and NK 
cells in HIV uninfected and infected individuals. CD16+ CD8 T cells from donors 
with CHI had higher expression levels and a more diverse array of KIRs on their 
surface, akin to KIR expression on NK cells, compared to CD16+ CD8 T cells 
in uninfected controls. CD16+ CD8 T cells express more KIRs in both disease 
states than the CD16- counterparts (Paper IV, Figure 2d). As KIR expression 
LVJHQHUDOO\DWWULEXWHGWR1.FHOOVVLPLODUWR&'WKLVVXJJHVWVWKDW)FȖ5,,,$
expressing CD8 T cells adopt an NK cell-like phenotype in CHI. Using a second 
cohort of longitudinally sampled donors from the Kayunga District in Uganda 
who initiated ART at chronic stages of HIV infection, the persistence of CD16+ 
CD8 T cells and their phenotype was measured 6- and 12-months post treatment 
initiation. Even 12 months post-treatment, there was no decline in the prevalence 
RI)FȖ5,,,$H[SUHVVLQJ&'7FHOOVEXWWKHUHZDVDGHWHFWDEOHGHFOLQHLQWKH
expression CD38 on their surface (Figure 16e and f).
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activated, terminally differentiated effector memory phenotype, and persist upon treat
ment initiation. a) Example staining of FcȖRIIIA (CD16) in CD8+ T cells amongst CD3+ 
cells in an HIV negative control and a chronically HIV infected donor, and the expression 
of CD38 and PD-1 on CD16+ CD8 T cells (red) compared to the CD16- CD8 T cells 
(gray). b) The frequency of CD16+ CD8 T cells and the expression of (c) CD38 and (d) 
PD-1 on CD16+ compared to CD16- CD8 T cells in HIV positive donors compared to HIV 
uninfected controls. e) The relative frequency of CD16+ CD8 T cells, or (f) the expression 
of CD38 on their surface before and after 6 or 12 months of ART in chronic HIV infection. 
Reprinted with permission from (299).
 7KH)FȖ5,,,$&'7FHOOVXEVHWKDVDQLQQDWHOLNH
transcriptional signature
$IWHUREVHUYLQJWKHXQLTXHSKHQRW\SHRI&'7FHOOVWKDWH[SUHVV)FȖ5,,,$JHQH
H[SUHVVLRQSURILOHVRIWKHVHFHOOVZHUHQH[WFRPSDUHGWRWKH)FȖ5,,,$FRXQWHU-
parts, central memory CD8 T cells, and NK cells. These four cell populations 
were sorted for targeted, multiplexed RT-qPCR to measure the expression of 96 
genes. 74 of these 96 gene assays passed quality control, and were subjected to the 
dimensionality reduction tool, Principal Component analysis (PCA). PCA revealed 
that that CD16+ CD8 T cells have a transcriptional profile that falls in between 
NK cells and CD16- CD8 T cells, and share no overlap with the central memory 
CD8 T cell population (Figure 17a3ULQFLSDOFRPSRQHQWFRQWULEXWHGWR
the variability of the dataset, with expression of genes GZMB, LAIR1, GZMK, 
PRF1, and CD244 contributing the most to this component. Principal compo-
QHQWFRQWULEXWHGRIWKHYDULDELOLW\LQWKHGDWDVHWZLWKGZMK, IL-6ST, 
TGFB1, CD38, and CD160 contributing the most to this principal  component. 
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FKDUDFWHULVWLFVJHQHUDOO\DVVRFLDWHGZLWK1.FHOOVD) Principal component analysis of 
74 genes measured using targeted multiplexed RT-qPCR analysis in four sorted cell popula-
tions; CD8+CD45RA-CD57- T cells (blue), CD8+CD45RA+CD57+CD16- T cells (red), 
CD8+CD45RA+CD57+CD16+ T cells (green) and CD56dim NK cells (purple) in 8 donors 
with chronic HIV infection. (b) Individual gene expression data from targeted multiplexed 
RT-qPCR, shown as 2ǻ&W, in four sorted cell populations in eight donors with chronic HIV 
infection. Reprinted with permission from (299).
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Looking at the individual gene level, it became evident that CD16+ CD8 T cells 
express higher levels of innate-like genes compared to CD16- or central memory 
CD8 T cells (Figure 17b). CD16+ CD8 T cells expressed higher levels of IKZF2, 
the gene that encodes the transcription factor Helios, than the other three cell 
 populations. Additionally, IL7R was expressed at lower levels, similar to NK cells, 
at both the gene expression (Figure 17b) and protein level as measured through 
IL-7R expression by flow cytometry (Paper IV, Figure 4c). CD16+ CD8 T cells 
also expressed higher levels of genes associated with cytoxicity, such as GRZMB 
(GrzB) and PRF1 (perforin), than the other CD8 T cell populations. NCR1, KLRF1, 
TNFSF13B, and CD244, genes also normally associated with NK cells and innate 
like function, were highly expressed by CD16+ CD8 T cells compared to the other 
CD8 T cells analyzed. 
High levels of the transcription factor Helios within this population inspired 
analysis of other transcription factors that influence T cell differentiation, includ-
ing Eomes and T-bet, at the protein level by flow cytometry. In chronically HIV 
LQIHFWHGGRQRUV&'7FHOOVH[SUHVVLQJ)FȖ5,,,$QRWRQO\H[SUHVVHGKLJKOHYHOV
of Helios, but also co-expressed Eomes and T-bet at levels higher than CD8 T cells 
WKDWGRQRWH[SUHVV)FȖ5,,,$Paper IV, Figure 3a and b). While CD16- CD8 
7FHOOVKDYHYDULDEOHH[SUHVVLRQRI7EHWDQG(RPHVDPHGLDQRIRI&'
CD8 T cells expressed a T-bethigh and Eomeshigh phenotype similar to that seen in 
NK cells (Paper IV, Figure 3b and c). Examination of the gene expression and 
the transcription factor profile of CD16+ CD8 T cells, their CD16- counterparts, 
and NK cells suggests CD16+ CD8 T cells inhabit a space in between conventional 
CD8 T cells and NK cells.
 )FȖ5,,,$&'7FHOOVSHUIRUP$'&&DIXQFWLRQ
generally attributed to NK cells
7KHQH[WVWHSZDVWRGHWHUPLQHLI)FȖ5,,,$H[SUHVVLQJ&'7FHOOFRXOGH[HFXWH
$'&&DIXQFWLRQJHQHUDOO\DWWULEXWHGWR)FȖ5,,,$H[SUHVVLQJ1.FHOOV$'&&
may be an important effector function in controlling HIV replication, as non-
neutralizing IgG antibodies are a correlate of protection in HIV vaccines (300). 
To do this, cells were FACS sorted and evaluated using the PanToxiLux assay, 
a flow cytometry based assay used to measure direct cytotoxicity of an effector 
cell against fluorescently labeled target cells through ADCC. Successful delivery 
of a lethal hit from a cytotoxic effector cell is measured through cleavage of a 
cell permeable fluorogenic substrate by granzyme and upstream caspase activity 
within the target cell.
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)LJXUH)FȖ5,,,$&'7FHOOVFDQIDFLOLWDWH$'&&D) Sorted cell populations CD8+ 
CD45RA- CD57- T cells, CD8+ CD45RA+CD57+ T cells (enriched for CD16+ CD8 
T cells), or NK cells were used in the PanToxiLux assay to measure the delivery of a cyto-
toxic hit to fluorescently labeled target cells (CEM.NKRCCR5 cell line) coated with gp120 
in the presence of polyclonal HIV-Ig as an antibody source. b) Measurement of granzyme 
delivered to target cells in the PanToxiLux assay by each respective sorted cell type, and 
(c) normalization on a per-CD16 expressing cell basis the granzyme delivered to target 
cells. Reprinted with permission from (299).
Since the monoclonal antibody against CD16 may block or trigger its downregula-
tion, CD16+ CD8 T cells were enriched for by sorting CD45RA+CD57+ CD8 
7FHOOVDQG)FȖ5,,,$1.FHOOVZHUHHQULFKHGIRUE\VRUWLQJ&'dim CD3- NK 
cells (Figure 18a). The CD45RA-CD57- CD8 T cells, which include very few 
CD16+ cells, were used as a negative control. HIV BaL gp120 coated NKR.
CEMCCR5 cells, which express CD4 and CCR5 and are resistant to spontaneous lysis 
by NK cells, were used as targets and co-incubated with one of the sorted effector 
cell populations in the presence of HIV-Ig as an antibody source (Figure 18a). 
CD56dim NK cells were able to facilitate ADCC at levels higher than the sorted T 
cell populations (Figure 18b). However when the killing activity was re-calculated 
based on the percentage of CD16+ cells present in the CD45RA+ CD57+ CD8 
7FHOOVDQG&'dim1.FHOOVLWZDVHYLGHQWWKDWWKH&'
CD8 T cells facilitated ADCC at a similar level as the NK cells on a per cell basis 
(Figure 18c7KHVHILQGLQJVLQGLFDWHWKDW&'7FHOOVH[SUHVVLQJ)FȖ5,,,$FDQ
facilitate HIV-specific ADCC at levels similar to NK cells.
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5 DISCUSSION AND FUTURE DIRECTIONS
HIV infection is a severe and persistent assault on the immune system, even in the 
presence of the effective therapies that are available today. The target of HIV is 
the immune system itself, creating a negative feedback cycle wherein the immune 
system is progressively depleted, further weakening the host while the virus con-
tinues to propagate into chronic infection and the progression to AIDS. The study 
of HIV immunopathogenesis will continue to be important in the absence of a 
preventative vaccine, the persistence of comorbidities even upon therapy initia-
tion, and no cure. This thesis hopes to further our understanding of the changes 
occurring in innate-like T cell subsets, a group of immune cells often overlooked as 
they are not the classically identified targets of HIV infection nor often considered 
players in controlling the virus itself. Exploring a unique, prospective cohort of 
individuals where pre- and post- infection time points are available in natural HIV 
infection (RV217), unconventional T cell dynamics were studied in the earliest days 
of HIV infection. This is a time period that sets the stage for disease progression 
into chronic infection. CD4+ iNKT cells, which are preferentially infected with 
HIV in vitro, decline significantly and more profoundly than conventional CD4 
T cells in the acute infection stage (Figure 19). The quantity of these cells pre- 
infection correlates positively with peak VL post HIV infection. These findings 
suggest iNKT cells may play a significant role in propagating HIV virus in acute 
infection, and contribute to the establishment of the elusive viral reservoir where 
HIV persists despite therapy. CD4- iNKT cells, however, decline at a slower rate 
than CD4+ iNKT cells, suggesting their loss is caused by other factors beyond 
direct viral infection per se. It is possible that iNKT cells may die because of 
chronic antigen exposure, or they may be lost from the blood due to recruitment 
to mucosal sites, as hypothesized for MAIT cell loss. 
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The iNKT cells and MAIT cells share many characteristics, such as the ability to 
recognize microbial antigen presented by evolutionarily conserved MHC class 
I-like molecules, and rapid innate-like effector function. However, this thesis 
supports the notions that these two unconventional cells subtypes differ in the 
temporal dynamics of their loss, phenotypic changes, and functional alterations 
in AHI. Therefore, they likely have differing roles in HIV immunopathogenesis. 
For example, there is a brief but significant expansion of MAIT cells (Figure 19), 
along with a boost in functionality post- peak VL, and this is not observed in 
iNKT cells. This expansion and cytotoxic functionality boost, along with increased 
expression of activation and exhaustion markers, may be driven by increasing 
microbial burden because of lowered gut integrity found in AHI, and engagement 
of the MAIT cell TCR. This is supported by findings that peak MAIT cell function 
and activation correlate with levels of the proposed marker of microbial transloca-
tion sCD14 (Paper II, Figure 7b). The loss of the important immunomodulatory 
CD4+ iNKT cells in the gut during AHI may be a significant contributing factor 
behind the increase in microbial translocation at this early time point, driving 
immune activation (Paper III, Figure 8). Both iNKT and MAIT cells experience 
a loss of functional capacity as chronic HIV infection begins, but the drivers of 
functional impairment may be different as well. MAIT cells upregulate check point 
inhibitory receptors already at this time point, while iNKT cells do not. It can be 
hypothesized that chronic TCR stimulation of MAIT cells drives their exhaustion 
and functional decline, as is the case with conventional CD8 T cells which share 
a similar exhausted phenotype and functional potential in chronic untreated HIV 
infection due to chronic antigen exposure. 
The immune system is elegantly collaborative. Its components have unique respon-
sibilities, but at the same time there is redundancy, in order to create an umbrella 
of protection in the host against whatever pathogen, and for however long the 
pathogen may endure. It is therefore not surprising that T cells have mechanisms of 
activation beyond TCR-dependent function to be used in instances where antigen-
specific response are exhausted. The expansion and maintenance of an enhanced 
innate-like phenotype, function, and transcriptional signature in the MAIT cell 
compartment in HIV infection, characterized by expression of the NK-marker 
CD56, may benefit the failing immune system in a chronic viral infection. With an 
DELOLW\WRUDSLGO\SURGXFHWKHDQWLYLUDOF\WRNLQH,)1ȖXSRQHQJDJHPHQWRI,/5
and IL18R on their surface, the maintenance of this directly innate responding 
subset of MAIT cells could prove to help fight the virus itself, as has been shown 
in other viral infections. However, the exact role of CD56 expressing MAIT cells 
in HIV infection has yet to be determined. 
Given that harnessing the innate-like functions of T cells may be a way of repur-
posing T cells towards alternate functions, it stands to reason that an adaptive 
&'7FHOOVXEVHWH[SUHVVLQJDPDUNHUFRPPRQO\IRXQGRQ1.FHOOV)FȖ5,,,$
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&'ZRXOGH[SDQGLQ&+,,WLVXQNQRZQLI)FȖ5,,,$H[SUHVVLQJ&'7FHOOV
are, in fact, HIV-specific CD8 T cells. However, it is interesting to speculate that 
the massive expansion of HIV-specific CD8 T cell clonotypes that exhaust their 
ability to be activated via TCR-mediated triggering would upregulate other effector 
mechanisms to help combat viral infection. HIV-targeted ADCC, the functionality 
IDFLOLWDWHGE\)FȖ5,,,$HQJDJHPHQWLVDFRUUHODWHRISURWHFWLRQLQ+,9YDFFLQH
efficacy and important for control of viral infections. Therefore, the repurposing 
of another cell type, beyond the normally utilized NK cell, to perform ADCC may 
benefit the host in an attempt to control viral replication. 
Further studies need to be performed to determine if enhanced innate functionality 
in conventional CD8 T cells or MAIT cells is beneficial to the host in HIV infection, 
or simply a consequence of a chronic viral infection. It has yet to be determined if 
iNKT cells also utilize an innate-like effector capacity in chronic HIV infection, 
however innate cytokine stimulation of iNKT cells contribute to control in other 
viral infections. Together, the findings of this thesis suggest innate-like T cells 
may have an important role in HIV immunopathogenesis, or at the very least, are 
engaged in HIV infection.
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